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ABSTRACT 
BIN3 is a novel 8p21 tumor suppressor gene that regulates the attachment checkpoint in 
epithelial cells 
Netonia Marshall 
An important characteristic of multicellular organisms is the control that the tissue 
architecture exerts on the fate of individual cells. Epithelial cells sense their location 
through interactions with the extracellular matrix (ECM) and remove themselves by 
programmed cell death (anoikis) when those interactions are disturbed. Importantly, 
anoikis is a line of defense that has to be circumvented by cancerous epithelial cells to be 
able to leave their home environment and establish long distance metastases. Here, by 
combining a genome-wide RNAi screen and a novel algorithm to study copy number 
alterations (ISAR-DEL), we identify the BridgingIntegrator3 (BIN3) as a novel 8p21 
tumor suppressor gene whose inactivation promotes escape from anoikis in epithelial 
cancers. Mechanistically, we link the tumor suppression function of BIN3 to its ability to 
relocate to the cell membrane after cell detachment and to induce a proapoptotic cascade. 
This death signaling is mediated by CDC42 activation of the P38α stress pathway and the 
consequent accumulation of the apoptotic facilitator BimEL. Our results identify BIN3 as 
a novel epithelial tumor suppressor gene, provide novel insights on the mechanisms of 
attachment tumor suppressor checkpoint and highlight the importance of anoikis escape 
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Regulation of anoikis by P38α and cell shape 
Breast cancer is a prevalent disease; in the United States, 1 in 8 women will be diagnosed 
with breast cancer during her lifetime (American Cancer Society). According to the National 
Cancer Institute, in 2013, there will be close to 250,000 new cases diagnosed and about 40,000 
breast cancer-related deaths, making breast cancer one of the most malignant diseases to afflict 
women in the United States. 
Metastatic cancers are the cause of about 90% of human cancer-related deaths and are the 
main cause of death in patients with breast cancer (Weigelt et al., 2005). Metastasis refers to the 
ability of cancer cells to leave a primary tumor, travel via the circulation system to distant 
tissues, and form secondary tumors. Metastasis is a complex, multi-step process, which 
commences with the detachment of cells from the extracellular membrane (ECM), invasion of 
those cells into adjacent tissue, intravastion (the intrusion of cancer cells into blood and 
lymphatic vessels), circulation (cells travel through the blood stream), extravastion (cells leave 
the blood stream by penetrating the endothelium), colonization, and ends with the growth of a 
secondary tumor (Leber and Efferth, 2009). 
Fortunately, metastasis is an inefficient process (Luzzi et al., 1998); studies show that 
about 0.01% of cancer cells injected into circulation were able to successfully form metastatic 
foci (Fidler, 1990). This inefficiency is due in part to programmed cell death induced by cell 
detachment or inappropriate attachment to the ECM; a phenomenon termed anoikis. Normally, 
when cells detach from the ECM or attach to inappropriate ECM, they experience anoikis (Frisch 
and Francis, 1994). Thus, for metastatic tumor cells, the ability to survive detachment and 




metastasis, while attachment to another tissue’s ECM (improper attachment) is one of the final 
steps before the formation of a metastatic cancer. Thus, anoikis is a self-eliminating strategy to 
protect against metastatic cells. Indeed, in vitro selection for anoikis-resistant cells increased the 
metastatic ability of cancer cells (Zhu et al., 2001). Therefore a better understanding of anoikis 
and the genes that regulate anoikis is essential to the study of cancer and the development of 
more efficient therapies against cancer. 
In mammary epithelial cells, anoikis is regulated by P38 mitogen-activated protein 
kinases (MAPK). P38 MAPK are a family of conserved serine/threonine kinases that mediate 
extracellular signals to intracellular proteins, propagate signaling cascades, and regulate many 
diverse cellular processes.  There are four known isoforms of P38 MAPK encoded by different 
genes that have been identified: P38α, P38β, P38γ, and P38δ (Han et al., 1994; Jiang et al., 1997; 
Li et al., 1996; Mertens et al., 1996). These isoforms share >60% overall sequence homology and 
>90% identity within the catalytic kinase domains, but despite their high homology, these 
isoforms have different expression in tissues and different upstream activators and downstream 
effectors.  P38α is ubiquitously expressed in most cell tissues (Lee et al., 1994; Li et al., 1996), 
while the other isoforms are expressed in a tissue-specific manner (Jiang et al., 1997; Lechner et 
al., 1996). P38α is considered the major isoform and to date is the best characterized isoform 
(Cuadrado and Nebreda, 2010). 
P38α was the first of the MAPK family to be identified; P38α was identified as a 38-kDa 
protein that was rapidly phosphorylated in response to LPS (lipopolysaccharide) stimulation 
(Han et al., 1994), as a target of drugs that inhibited the production of pro-inflammatory 
cytokines (Lee et al., 1994), and as an activator of MAPK-activated protein kinase 2 in heat 





Introduction Figure 1. The MAP3K-MAP2K activation pathway (Coulthard et al., 2009).   
 
P38 MAPK can be phosphorylated through the MAPK kinase kinases (MAP3K)–MAP 
kinase kinases (MAP2K) pathway. The MAP3K-MAP2K pathway is triggered by an external 
stimuli or signal (such as osmotic stress, shear UV radiation, hypoxia, or more), which activates 
upstream effector of the cascade (such as RAC1 or CDC42). Activation of the upstream 
activators leads to the phosphorylation and activation of the first tier of the cascade, MAP3K. 
Prorogating the signal, MAP3K leads to the phosphorylation of the second tier, the MAP2K. 
MAP2K dual phosphorylate MAPK, in this case P38α, on the Threonine-Glycine-Tyrosine motif 
in the activation loop. Different MAP2K phosphorylates different isoforms of P38 MAPK 
depending on the stimulus and cell type (Thompson et al., 1994). Phosphorylated P38 MAPK 




More recently, P38 MAPK have been implicated in varied cellular processes, such as the 
regulation of the cell cycle, induction of cell death, differentiation, and senescence. These data 
have come together to suggest an anti-tumorigenic role for P38 MAPK, especially for P38α. 
Mouse embryo fibroblasts (MEFs) deficient in either P38α (Dmitrieva et al., 2002) or its 
activators MKK3 and MKK6 (Brancho et al., 2003) produced larger oncogene-induced tumors in 
mice.  P38α can suppress tumor formation by inducing terminal differentiation (Puri et al., 2000) 
or by negatively regulating cell cycle progression by inducing a G1/S delay in response to stress 
either by downregulating cyclin D1 (Lavoie et al., 1996) or by upregulating p16INK4a (Bulavin 
et al., 2004; Wang et al., 2002). Furthermore, P38α has been shown to play a pro-apoptotic 
function in many different contexts. P38α can modulate the expression and activity of the tumor 
suppressor p53 both at the transcriptional and posttranslational levels to induce apoptosis 
(Mikule et al., 2007; Perfettini et al., 2005). P38α activation can lead to the upregulation of pro-
apoptotic proteins BAX and FAS-receptor and the downregulation of pro-survival pathways 
(Porras et al., 2004). Finally, P38α can stimulate the pro-apoptopic function of BIM during 
anoikis (Wen et al., 2011). 
 





In mammary epithelial cell line MCF-10A, P38α is phosphorylated and activated by MEKK 3/6 
(Wen et al., 2011) during detachment from the ECM (Mailleux et al., 2007). Phosphorylation of 
P38α at Threonine 180/Tyrosine 182 induces a conformational change in the protein which 
enables ATP and substrates to bind (Brancho et al., 2003). Active P38α phosphorylates 
transcription factor ATF-2 at Threonine 71/Threonine 69; phosphorylation of ATF-2 increases 
the transcription of c-Jun (Raingeaud et al., 1995). ATF-2 and c-Jun heterodimerize, along with 
other components of Activating Protein 1 (AP-1), to stimulate the transcription of BIMEL (extra-
long form of BIM). Therefore, the phosphorylation of P38α leads to the transcriptional activation 
and upregulation of the apoptotic facilitator protein, BIMEL via ATF-2 and c-JUN (Intro Fig. 2) 
(Wen et al., 2011).  
BIM is a pro-apoptotic BH3-only member of the BCL-2 family. The BH3 domain of 
BIM can interact with other the BH1, BH2, and BH3 domains of other BCL-2 members and 
modulates their functions (Cheng et al., 1996; Muchmore et al., 1996; Strasser et al., 2000). BIM 
is able to promote apoptosis in two ways: 1.) BIM is able to bind anti-apoptopic proteins, BCL-2 
and BCL-XL (BCL-extra-long form), block their anti-apoptopic activity, and free BAX and/or 
BAK to promote apoptosis (Adams and Cory, 1998); and/or 2.) BIM is an “activator” of 
apoptosis and BIM is able to bind BAX or BAK, assist the release of CYTOCHROME C, and 
death machinery into the cytoplasm (Adams and Cory, 1998) .  
In mammary epithelial cells, it has been shown that during detachment BIMEL locates to 
the mitochondria and binds BCL-XL (Reginato et al., 2003). BIM displaces BCL-XL at the 
mitochondria, promotes the translocation and oligomerization of BAX to the mitochondrial 




mitochondrial outer membrane permeabilization which releases CYTOCHROME C into the 
cytoplasm (Intro Fig. 3) (Korsmeyer et al., 2000). 
 
Introduction Figure 3. Intrinsic Apoptosis Pathway (Vachon, 2011). 
 
In the cytoplasm, CYTOCHROME C binds APAF-1; this biding promotes the 
recruitment of the inactive version of CASPASE 9 (pro-CASPASE-9). Together these proteins 
form the apoptosome. The apoptosome facilitates the proteolytic activation of pro-CASPASE 9 
and cleavage to active CASPASE 9. Active CASPASE 9, in turn, proteolytically activates 
downstream caspases that kill cells by cleaving important intracellular proteins (Intro Fig. 3) 
(Vachon, 2011). Thus, P38α links detachment from the ECM to BIMEL upregulation and 
apopotosis.  
There are two known mechanisms that alert the cell to detachment from the ECM (and 
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(e.g., tBid, Bim, and Puma)
CAD activation
Effector Bcl-2 homologs
Figure 1: Intrinsic pathway of apoptosis. As decisional checkpoint of entry in apoptosis, Bcl-2 homologs perform functions—among
many—in the integrity of the mitochondrion and thus regulating the formation of the apoptosome. Anti-apoptotic suppressor homologs
inhibit their pro-apoptotic e!ector counterparts, preventing their translocation to the mitochondrion in order to create pores (and thus
releasing cytochrome c and IAP inhibitors such as Smac/Diablo). Additional pro-apoptotic sensitizer and activator homologs act to inhibit
the suppressors, although activators can furthermore interact with e!ectors to activate or enhance the functions of the latter. When the
balance of Bcl-2 homologs is in favor of pro-apoptotics, e!ectors are free at the mitochondrion to homo-oligomerize, or hetero-oligomerize,
with fellow e!ectors, and/or with activators, thus a!ecting the integrity of the mitochondrial membrane. APAF-1 and released cytochrome
c can cooperate to dimerize pro-CASP-9, thus forming the apoptosome, resulting in massive CASP-9 activation and subsequent amplifying
activation cascade of executioner caspases. Note that only the general outlines are shown here, for the sake of clarity. PARP, poly(ADP Ribose)
polymerase; scissors: caspase-mediated cleavage.
[1–10]. In typical instances of apoptosis, the death throes
of a dying cell comprise membrane blebbing, chromatin
condensation, DNA degradation, organelle destruction, and
cell shrinkage [1–10]. Ultimately, the process results in the
formation of apoptotic bodies that are either phagocytosed
(by macrophages or eighboring cells), or simply released
into a lumen for subsequent evacuation [1, 2, 4, 7–9, 13].
The Bcl-2 (“B-cell chronic lymphocytic leukemia/lym-
phoma 2”) family of proteins—or homologs—is well known
to constitute a critical decisional center of cell survival and
apoptosis [6, 8, 11, 12, 14–17]. Some twenty members of
this family have been identified so far in man [11, 12, 14–
17]. While most Bcl-2 homologs are ubiquitously expressed
regardless of the cell type [6, 8, 11, 12, 14–17], some may
be prominently, or even selectively, expressed in a more
restricted subset of tissues [6, 8, 11, 12, 14–17]. Alternately,
some homologs will become expressed following specific
apoptotic stimuli. A classic example of this is the p53-driven
induction of the expression of the pro-apoptotics Puma and
Noxa following DNA damage, consequently forcing cells to
undergo apoptosis [6, 8, 11, 12, 14–17]. Bcl-2 homologs act
primarily as apoptotic suppressors (“anti-apoptotics”; e.g.,
Bcl-2, Bcl-XL, Mcl-1), e!ectors (“pro-apoptotics”; namely,
Bax, Bak, and Bok), activators (pro-apoptotics; e.g., Bid/tBid,
Bim, Puma), or sensitizers (pro-apoptotics; e.g., Bad, Bmf,
Bik, Noxa) (Figure 1) [6, 8, 11, 12, 14–17]. In general,
the suppressors interact with the e!ectors in the cytosol
to prevent e!ector translocation to mitochondria. Alter-
nately, suppressors will bind e!ectors already present at
mitochondrial membranes in order to prevent them from
oligomerizing (Figure 1) [6, 8, 11, 12, 14–17]. Upon a given
apoptotic stimulus, the balance of anti- and pro-apoptotic
homolog expression and activities will be a!ected so that
the sensitizers and activators gain the upper hand, therefore
allowing both groups to inhibit suppressors (Figure 1) [6,
8, 11, 12, 14–17]. Additionally, activators will synergize with
e!ectors to either help the latter translocate to mitochondria,
or oligomerize with them at mitochondrial membranes
(Figure 1) [6, 8, 11, 12, 14–17]. The end result is that
e!ectors are now in force at mitochondrial membranes and
are free to homo-oligomerize, or hetero-oligomerize, with










could trigger subsequent P38-signaling and anoikis): 1.) the disruption of integrins and integrin-
signaling; and 2.) cell rounding and the accompanying cytoskeletal rearrangement. Cellular 
attachment to the ECM is mediated by integrins, heterodimeric transmembrane receptors, which 
serve as a direct link between the ECM and the cytoskeleton of the cell (Chicurel et al., 1998). 
There is extensive literature implicating the role of integrin-signaling in survival and the 
suppression of anoikis (Boudreau et al., 1995; Frisch and Ruoslahti, 1997; Gilmore, 2005; 
Meredith et al., 1993). While the role of integrins and integrin-signaling in anoikis regulation is 
undeniable, there are many data that suggests that integrin engagement and integrin-signaling is 
not enough to rescue cells from anoikis.  
In vivo, rounded capillary endothelial cells still bound to the ECM by integrins 
experienced anoikis (Ingber, 1990). Cell detachment causes profound changes in cell shape and 
cytoskeletal reorganization; detached cells round (Ingber, 1990). When endothelial cells were 
plated in suspension (plates treated with poly(HEMA) to prevent the cells from attaching), the 
cells rounded, and underwent anoikis (Frisch and Francis, 1994). Futhermore, when the cells 
were plated in suspension plates with beads coated with RGD sequence (the RGD sequence is 
found in the integrin-binding sites of many matrix proteins and this sequence is sufficient and 
able to occupy and engage integrins (Ruoslahti, 1996)), even though the beads were able to 
engage the integrins of the cells, because the beads forced the cells to retain a circular shape, the 
cells still underwent anoikis (Re et al., 1994). The role of cell shape in anoikis regulation has 
been extensively explored (Chen et al., 1997; Re et al., 1994). Chen et al., (1997) devised a 
system in which they were able to manipulate the shape of cells, while keeping equal the surface 
area onto which the cells were attached, the total number of focal adhesions, total cell to ECM 




were still susceptible to anoikis, while cells that were not round were rescued from anoikis. 
These results show that cell shape is an important regulator of apoptosis and that round, highly 
curved conformation can trigger anoikis. 
BAR domain family: a family of membrane curvature sensors  
The BAR (Bin, Amphiphysin, Rvs) domain superfamily is a family of proteins that 
preferentially binds highly curved, round membranes (McMahon and Gallop, 2005), suggesting 
that BAR domain proteins have the ability to sense and discern membrane curvature. Once BAR 
domain proteins bind to curved membranes, they then exhibit their biological functions based on 
membrane shape, a phenomenon termed membrane sensing (McMahon and Gallop, 2005). 
Membrane sensing is the first canonical function of the BAR domain family.  
The common feature of this family is a homologous BAR domain. The BAR domain is a 
domain of ~250-280 amino acids residues that is conserved throughout evolution. 
Architecturally, the BAR domain is a kinked, tri-helical coiled-coil that forms banana-shaped 
dimers with a positively charged concave faces. The architecture of the BAR domain facilitates 
the ability of the BAR domain to bind to membranes (Peter et al., 2004). Members of the family 
have been implicated in a wide variety of processes including endocytosis, vesicle trafficking, 
stress signaling, cell polarity, actin organization, signal transduction, tumor suppression, 
apoptosis, cell-cell fusion, tissue differentiation, ion channel signaling, and more (Ren et al., 
2006). 
Amongst the family there are six major subgroups: classical BAR, N-BAR, F-BAR, PX-
BAR, BAR-PH, and I-BAR (Frost et al., 2009). The N-BAR subgroup is defined by the presence 
an α-helix in the N-terminal. α-helices are general membrane binding motifs that are found in 




and absorb into the membrane allowing proteins to bind the membrane (Dunne et al., 1996). α-
helices have one face that is hydrophobic and one is that hydrophilic, modeling the amphipathic 
nature of lipid bilayer membranes. Exploiting this amphipathic nature, the hydrophobic face of 
α-helices motifs embed within the fatty acyl chains of the lipid bilayers, while the hydrophilic, 
polar residues of the motif embed into the lipid polar heads of lipid bilayers (Hristova et al., 
1999). Insertion and absorption into the membrane is further stabilized by electrostatic 
interactions between the positive residues in the polar face of the motif and negatively charged 
lipids (Hristova et al., 1999).  
When lipid membranes are highly curved, lipid packing defects (gaps in the membranes) 
are introduced to compensate the tension introduced by high curvature (Nuscher et al., 2004). α-
helices are able to insert their hydrophobic face into these packing defects (Chen et al., 2007; 
Cornell and Taneva, 2006). Inserting into these defects allows α-helices to fold in to their correct 
helical confirmation and be stabilized. High curvature introduces both more lipid packing defects 
and larger lipid packing defects, in turn, giving α-helices more binding spots and binding spots 
that are large enough to contain correctly folded α-helices. When membranes are not curved, 
there are less packing defects and there is an absence of defects large enough for α-helices to fold 
into their correct α-helix confirmation, thus, preventing proper absorption into the membrane and 
membrane binding (Hatzakis et al., 2009). Thus, by exploiting the α-helix motif in the N-
terminal, N-BAR proteins are able to sense membrane curvature, preferentially bind, and 
upconcentrate at curved membrane. At high concentrations of bound N-BAR proteins, 
membranes start to increase curvature and deform, thus inducing membrane curvature, the 






BIN3 plays a role in CDC42 activation and tumor suppression 
The third canonical function of the BAR domain family is binding small GTPases and 
GTPase-binding proteins (Habermann, 2004). Arfaptins were the first BAR domain proteins 
identified that were able to bind GTPases. ARFAPTIN1 and ARFAPTIN2 bind RAC GTPases 
and RAC-interacting proteins (Van Aelst et al., 1996) via the BAR domain (Nakamura et al., 
2012; Tarricone et al., 2001). Other members of the BAR domain family have since been 
identified to be able to bind GTPases. 
  One such BAR domain protein is hob3p, the Schizosaccaharomyces pombe (S. pombe) 
homolog of human BIN3 (hob3p). Both BIN3 (Bridgingintegrator-3) and hob3p are 
compromised solely of a BAR domain (Routhier et al., 2001). During cytokinesis, hob3p 
complexes with cdc42p (yeast homologue of CDC42 (Cell Division Cycle 42)) and, the activator 














CDC42 belongs to the Rho GTPase family. Rho GTPases constitute a family within the 
superfamily of Ras-related small GTPases and are found in all eukaryotic cells. Rho GTPases act 
as molecular switches that cycle between GTP-bound and GDP-bound state. When Rho GTPases 
are bound to GTP they are considered active and able to through conformation-specific 
interactions signal and engage effectors, conversely, when GTPases are bound to GDP they are 
considered inactive and are unable to bind effectors. Guanine nucleotide exchange factors 
(GEFs) facilitate the binding of GTP to Rho GTPases and, thus, activate Rho GTPases, while 
GTPase-activating proteins (GAPs) facilitate the dissociation of GTP, and thus, inhibit GTPase 
function (Etienne-Manneville and Hall, 2002). 
 
 













In yeast, cdc24p controls cell polarization (Chang and Peter, 2003; Martin and Chang, 
2003). Cell polarity is spatial differences in the shape, structure, and function of cells. These 
differences enable cells to carry out specialized functions. Yeast cells grow isotropically until 
they reach a critical size and form a bud and divide. In the absence of cdc42p, cells are no longer 
polarized and instead gives rise to large, round, unbudded cells (Adams et al., 1990). Cdc42p 
activation leads septin organization, actin and microtubule reorganization and polarization, and 
membrane trafficking to promote proper cytokinesis (Etienne-Manneville, 2004). A key step 
during polarization is the localized activation of cdc42p at the new growth site.  
During cell division, hob3p complexes with cdc42p and localizes cdc42p to contractile 
ring of dividing cells. Once cdc42p is localized to the contractile ring, hob3p complexes with 
gef1 to allow gef1 to activate cdc42p. Active cdc42p targets other proteins necessary for 
ensuring proper cell polarity and cytokinesis. When S. pombe cells lack hob3p, cdc42p is unable 
to be correctly activated, resulting in multisepated cells and mislocalized F-actin patches (Coll et 
al., 2007). Human BIN3 was able to complement and rescue the phenotype of hob3p lacking 
cells, restoring proper cdc42p activation (Coll et al., 2007; Routhier et al., 2001), suggesting 
some conserved functional overlap between S. pombe hob3p and human BIN3. 
Recently, the conserved role of human BIN3 in the activation of human CDC42 was 
confirmed; loss of BIN3 attenuated the levels active CDC42 in myoctyes and muscle cells 
(Simionescu-Bankston et al., 2013). A more defined role of BIN3 in higher eukaryotes is still 
being elucidated.  
In humans, BIN3 has been implicated in the suppression of tumor formation. Bin3 knock 
out mice showed significantly increased incidence of lymphomas and lung cancers (Ramalingam 




prone to invasion, resistance to anoikis, and increased proliferation (Ramalingam et al., 2008) 
common characteristics of cancerous cells. Furthermore, Xue et al. found that knock down of 
Bin3 produced larger hepatocellular tumors in mice as compared with control mice (Xue et al., 
2012). Finally, shRNAs against Bin3 were identified during a screen for their ability to increase 
the lymphomagenic potential and increase lymphomagenesis of pre-malignant haematopoietic 
stem and progenitor cells from MYC-overexpressing transgenic mice (Scuoppo et al., 2012). 
Bin3 knock down produced tumors and significantly reduced the survival of these mice. All 
these data suggest that BIN3 plays a currently unknown role in the suppression of cancer. 
 
 
8p a tumor suppressor ‘hot spot’ 
BIN3 lies on the short arm of chromosome 8 (8p), a chromosomal region that has been 
deleted in many different types of epithelial cancers and a region that is highly implicated in 
cancer suppression. Chromosomal loss is one of the most frequent events in cancer progression. 
Frequent loss of a chromosomal region in cancers suggests the presence of a gene which the loss 
of the gene is beneficial to the progression of cancer (tumor suppressor) (Harris et al., 1969). 
Loss or inactivation of tumor suppressors is one major drivers of cancer progression 
(Cavenee and White, 1995). There are three ways chromosomal deletion may impair tumor 
suppressor function: 1.) heterozygous deletion of a gene may lead to haploinsufficiency (when 
only one functional copy of a gene is not enough to bring about wildtype-like state (Jenkins et 
al., 1984; Santarosa and Ashworth, 2004)); 2.) heterozygous deletion plus another ‘hit’ 




(Knudson, 1971; Knudson et al., 1973); or 3.)  homozygous deletion leads to complete of loss 
protein and function.  
The short arm of chromosome 8 (8p) is one of the most frequently deleted regions during 
tumorigenesis; deletion occurring in as many as 60% of epithelial tumors of various origin. Thus, 
this region is strongly suggested contain at least one tumor suppressor, though is expected to 
house as many as three tumor suppressors (Anbazhagan et al., 1998; Chang et al., 2007; Rubio-
Moscardo et al., 2005; Venter et al., 2005; Ye et al., 2007; Yokota et al., 1999). The frequent 
deletion of this region was first identified in hepatocellular carcinomas, ovarian, lung, and gastric 
cancers (Emi et al., 1992).  
In an effort to eliminate tumor suppressors, neighboring genes are also deleted, making it 
difficult to discern which genes in the deleted region are tumor suppressors and which genes are 
merely ‘causalities.’ Many studies have aimed to identify the tumor suppressor(s) on 8p. To date 
there have been many candidates identified as potential tumor suppressors from this region, but 
no one gene has yet emerged that can fully account for a tumor suppressor that can play an 
important role in the tumorigenesis of so many different types of cancers. Here there will be a 
short review on some of the most prominent candidates from this region.! 
FEZ1 (also known as LZTS1) maps to the chromosomal region 8p22. Alterations in 
FEZ1 expression have been observed in such cancers as esophageal, breast, and prostate cancers  
(Ishii et al., 2001). Introduction of FEZ1 into FEZ1-negative cancer cells reduced cell growth 
and caused the cells to accumulate at late S-G2/M stage. Introduction of FEZ1 also suppressed 
the tumorigencity of cells. Further studies revealed that FEZ interacts with p34cdc2 at late S-G2/M 
stage in vivo (Ishii et al., 2001). P34cdc2 regulates mitotic initiation and the transition into M 




regulation of mitosis, and conversely, alterations in FEZ1 result in abnormal cell growth (Ishii et 
al., 2001). 
 
Introduction Figure 6. The commonly deleted 8p region and candidate tumor suppressor genes in various 
cancers. Adapted from Birnbraum et al.,2003!
 
Cub and Sushi Multiple Domains-1 (CSMD1) is a candidate tumor suppressor gene that 
maps to 8p23 (Kamal et al., 2010). Loss of CSMD1 was detected in 50-80% of head and neck 
cancers, 46%-90% of lung cancers, and 55% of breast cancers. Moreover, loss of CSMD1 is 
associated with poor prognosis (Kamal et al., 2010). CSMD1 is expressed strongly in the central 
nervous system and is expressed at low levels through the gastrointestinal system. The 




gastrointestinal tract, and skin suggests that CSMD1 may play a role in mammalian epithelial 
regeneration (Ma et al., 2009).  
Secreted Frizzled-Related Protein (SFRP1) maps to 8p11. In bladder cancers, 66% 
showed reduced protein expression (Stoehr et al., 2004), while in colon, lung, and ovarian 
cancers SFRP1 expression is frequently inactivated by promoter methylation (Veeck et al., 
2006). SFRP1 loss was associated with higher tumor grade and stage and shorter overall survival 
(Stoehr et al., 2004). SFRP1 produces a soluble antagonist and negative regulator of the Wnt 
pathway (Katoh and Katoh, 2006; Veeck et al., 2006), a pathway that has been well established 
to play a key role during embryogenesis and defects in this pathway have been implicated in the 
pathogenesis of various types of tumors (Katoh, 2005). 
Neuregulin-1 (NRG1) is both a candidate oncogene and a candidate tumor suppressor 
gene. NRG1 maps to 8p12 and encodes ligands that bind to the ERBB/HER/EGFR family of 
receptors (Sheng et al., 2010), a family of receptors that are well documented to play tumorigenic 
role in many types of cancers. Although ERBB/HER/EGFR and NRG1-encoded proteins are 
usually thought of as mitogens, NRG1 can also play a pro-apoptotic role: expressing NRG1 in 
cells that express NRG1 can cause apoptosis (Chua et al., 2009). Furthermore, the NRG1 gene is 
frequently inactivated in breast cancer. The absence of expression of NRG1 was often associated 
with DNA methylation of CpG island in the promoter site for NRG1 and most tumors also 
showed DNA methylation. Reducing NRG1 expression in cell lines increased cell proliferation 
(Chua et al., 2009).   
Whether NRG1 acts as a tumor suppressor gene or as an oncogene is currently unknown. 
Recurrent breaks in the NRG1 gene occurs in 6% of breast cancers as well in some lung and 




translocation: recently, a translocation was found in the NRG1 gene- t(8;11) translocation 
(Huang et al., 2004). This translocation fuses the 3’ end of NRG1, including the receptor-binding 
domain, to DOC4. DOC4 is a stress-induced gene located at 11q13. This gene fusion between 
NRG1 and DOC4 results in a secreted, chimeric ligand that is able stimulates cell growth, 
promote tumorignecity, and metastasis. NRG1 potentially encodes more than a dozen protein 
isoforms, thus the effect of NRG1 on cell growth may be variable. 
DBC2 (Deleted in Breast Cancer 2), also called RhoBTB2, was cloned from a 
homozygously deleted region at human chromosome 8p21 (Hamaguchi et al., 2002). Deletion or 
loss of DBC2 is associated with mammary oncogenesis (Hamaguchi et al., 2002).  DBC2 was 
identified as a direct target of the E2F1 transcription factor (Freeman et al., 2008).  E2F1 is a 
direct target of bonafide tumor suppressor RB and E2F1 is also involved with in the activation of 
other bonafide tumor suppressors ATM and P53 during apoptosis (Powers et al., 2004).  
The NKX3.1 gene maps to 8p21 (He et al., 1997). NKX3.1 is a prostate-specific tumor 
suppressor gene. “NKX3.1 plays a role in the opposing processes of androgen-driven 
differentiation of prostatic tissue and loss of differentiation during the progression of prostate 
cancer” (He et al., 1997).  Loss of a single allele of NKX3.1 predisposes to prostate 
carcinogenesis. NKX3.1 has been found to be a critical event in prostate cancer initiation (Kim et 
al., 2002). 
 To date the most functionally validated candidate for a tumor suppressor in the 8p region 
is Deleted in Liver Cancer 1 (DLC1). First identified in liver cancer, DLC1, located at 8p22, 
encodes a Rho-GTPase Activating Protein (RhoGAP) (Yuan et al., 1998). This protein catalyzes 
the conversion of active, GTP-bound form of RHOA to the GDP-bound form, rendering RHOA 




RHOA and are more tumorigenic. DLC1 negatively regulates Rho/ROCK/MLC2 pathway and 
suppresses metastasis and migration of cancer cells. Rho-kinase (ROCK) is an immediate down-
stream effector of RHOA that mediates cellular cytoskeletal events and cell motility (Wong et 
al., 2008).  DLC1 is also deleted, mutated, and exhibit promoter methylation in lung, breast, 
colon carcinomas, and DLC1 has shown to be able to suppress metastasis and tumorigenicity in 
breast and lung cancer cells (Healy et al., 2008; Yuan et al., 2003). 
Unfortunately a gene that can account for the extensive alterations seen in 8p in various 
tumors has yet to materialize, despite all the potential candidates (Birnbaum et al., 2003). Since 
no one candidate gene that can account for the extensive alterations witnessed in so many 
different types of cancers has emerged, a theory has emerged that supposes that frequent 
deletions in chromosomes arise from selective pressure to attenuate the activity of multiple genes 
rather than a single gene. To test this theory, Xue et al. (2012) screened and knocked down the 
mouse orthologs of candidate tumor suppressors from 8p; they found that multiple genes on 
chromosome 8p (DLC1, FG11, TRIM35, FBXO25) can cooperate to inhibit tumorigenesis in 
mice and that their co-suppression can synergistically promote tumor growth (Xue et al., 2012). 
Furthermore in patients, the combined down-regulation of multiple genes on 8p is associated 
with poor survival in contrast to the down-regulation of any individual gene (Xue et al., 2012). 
These data imply that individual tumor suppressor genes can cooperate to better suppress tumor 
formation, but it is still important to identify and study individual novel tumor suppressors to 
increase our understanding of cancer biology. 
 




The advent of new technology has greatly aided the search for novel tumor suppressors 
and has refined the narrowing down of deleted regions. One such technology is GISTIC 
(Genomic Identification of Significant Targets in Cancer), a statistical approach that identifies 
regions of aberration that are more likely to be altered because they are crucial to tumorigenesis 
rather than by random chance (Beroukhim et al., 2007). GISTIC is an algorithm that utilizes raw 
array data to preform computational analysis to distinguish between causal chromosomal 
deletions from functionally neutral ones.   
 




“GISTIC scores each location separately for gains and losses. The G score produced by 
GISTIC accounts for both the frequency of the occurrence of the aberration and the 
magnitude of the copy number change to identify regions of interest. Then, locations in 
each sample are permuted simulating data with random aberrations. This random 
distribution is compared to the observed statistic to identify scores that are significant. 
FDR multiple testing correction is applied to calculate a Q-bound significance score. 
Within each statistically significant region, a peak region is identified so that the region 




Only regions that pass both the G-Score and Q-bound threshold cut-offs will be shown 
(Intro Fig. 7)(Attolini and Michor, 2009).” 
As proof of concept, GISTIC was able to identify almost all the known genes to be involved in 
glimoa tumorigenesis (Beroukhim et al., 2007) 
Further aiding the search of genes instrumental to cancer progression, there has been the 
collection of large patient samples with clinical information, such as The Cancer Genome Atlas 
(TCGA). TCGA, an initiative pioneered by the National Cancer Institute and the National 
Human Genome Research Institute, is a “comprehensive and coordinated effort to accelerate the 
understanding of the molecular basis of cancer through the application of genome analysis 
technologies, including large-scale genome sequencing. TCGA researchers analyze tumor and 
normal tissue from hundreds of patients for each cancer selected for study. This provides the 
statistical power needed to produce a complete genomic profile of each cancer, which is crucial 
to identifying those genomic changes that offer the greatest opportunities for therapeutic 
development. The information that is generated by the TCGA is entered into public databases as 
it becomes available, allowing scientists to continually access the information (TCGA, 2012).”  
Collections like TCGA and others (like METABRIC and cBioPortal) provide large scale, 
genomic data of primary tumors and provide mRNA, microRNA expression data, non-
synomymous mutational analysis, protein level and phosphoprotein level (RPPA) data, DNA 
methylation data, and clinical data to researchers. Algorithms can use information from TCGA to 
further narrow down deletions and accurately elucidate tumor suppressors.  
Finally, loss-of-function studies have also greatly aided the elucidation of tumor 




absence of the gene of interest provides evidence for the function of the gene. RNA interference 
(RNAi) is used in loss-of-function studies to silence specific genes.  
RNAi and the RNAi processing pathway were first described in C. elegans (Fire et al., 
1998; Guo and Kemphues, 1995). RNAi is a regulatory mechanism of cells in response to small 
double-stranded RNA (dsRNA) molecules; dsRNA triggers degradation of complementary 
sequences.  
Introduction Fig. 8. MiRNA biogenesis (Winter et al., 2009). 
 
MicroRNAs (miRNAs) are an important branch of RNAi studies. MiRNAs are endogenous, 
small regulatory RNAs that are generated from long primary miRNAs (pri-miRNAs). Pri-
miRNAs are processed in the nucleus by the Microprocessor complex (comprised of the 
DROSHA and DGCR8) to ~60–70 nt (nucleotide) precursor miRNA (pre-miRNA) intermediates 
(Denli et al., 2004; Gregory et al., 2004; Han et al., 2004). Microprocessor specifically cleave the 
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pri-miRNA cleavage by the Drosha–DGCR8 microprocessor complex. 
The pri-miRNA is next endonucleolytically cleaved by the nuclear micro-
processor complex formed by the RNase III enzyme Drosha (RNASEN) 
and the DGCR8 (DiGeorge critical region 8) protein (also known as Pasha 
(Partner of Drosha) in D. melanogaster and C. elegans)36 (Fig. 2a). DGCR8/
Pasha contains two double-stranded RNA-binding domains and is essen-
tial for miRNA processing in all organisms tested37–40. An average human 
pri-miRNA contains a hairpin stem of 33 base-pairs, a terminal loop and 
two single-stranded flanking regions upstream and downstream of the 
hairpin. The double-stranded stem and the unpaired flanking regions 
are critical for DGCR8 binding and Drosha cleavage, but the loop region 
or the specific sequences are less important for this step41–43. A single 
nucleotide polymorphism in a miRNA precursor stem can block Drosha 
processing44. Nevertheless, many miRNA sequence aberrations observed 
in human tumours alter the secondary structure without affecting process-
ing, and reveal the structural flexibility of the microprocessor34.
The two RNase domains of Drosha cleave the 5´ and 3´ arms of the pri-
miRNA hairpin39, whereas DGCR8 directly and stably interacts with the 
pri-miRNA and functions as a molecular ruler to determine the precise 
cleavage site41. Drosha cleaves 11 base pairs away from the single-stranded 
RNA/double-stranded RNA junction at the base of the hairpin stem.
Drosha-mediated cleavage of the pri-miRNA occurs co-transcriptionally 
and precedes splicing of the protein-encoding or non-coding host RNA 
that contains the miRNAs. Splicing is not inhibited by Drosha-mediated 
cleavage, because a continuous intron is not required for splicing45,46.
microRNA-specific regulation of the microprocessor complex. 
Drosha-mediated pri-miRNA processing was recently shown to be 
subject to regulation by miRNA-specific mechanisms. Drosha forms 
two different complexes, a small microprocessor complex that contains 
only Drosha and DGCR8 and processes many pri-miRNAs, and a larger 
complex that contains RNA helicases, double-stranded RNA binding 
proteins, heterogeneous nuclear ribonucleoproteins and Ewing’s sarcoma 
proteins38. The RNA helicases p72 and p68 are part of the large Drosha 
complex and might act as specificity factors for the processing of a sub-
set of pri-miRNAs (Fig. 2b). Expression levels of several miRNAs are 
reduced in homozygous p68!/! or p72!/! knockout mice, whereas other 
miRNAs remain unaffected47.
Drosha-mediated cleavage can also be regulated for individual miR-
NAs: the heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) 
binds specifically to pri-miR-18a and facilitates its processing. Loss of 
hnRNP A1 diminishes the abundance of mature miR-18a (Fig. 2c), but 
hnRNP A1 does not have any impact on other miRNAs that are located 
in the same miR-17 genomic cluster, demonstrating the extraordinary 
specificity of miR-18a biogenesis48. hnRNP A1 binds to the conserved 
loop of the pri-miR-18a and changes the hairpin conformation to create 
a more favourable cleavage site for Drosha49. About 14% of the human 
pri-miRNA loops are conserved between different species and could 
provide anchor points for similar regulatory mechanisms.
Transf rming growth factor-" (TGF-") and bone morphogenetic 
factors (BMPs) induce the maturation of miR-21 by regulating the 
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Figure 1 The ‘linear’ canonical pathway of microRNA processing. The miRNA 
processing pathway has long been viewed as linear and universal to all 
mammalian miRNAs. This canonical maturation includes the production of 
the primary miRNA transcript (pri-miRNA) by RNA polymerase II or III and 
cleavage of the pri-miRNA by the microprocessor complex Drosha–DGCR8 
(Pasha) in the nucleus. The resulting precursor hair in, the pre- NA, i  
exported from the nucleus by Exportin-5–Ran-GTP. In the cytoplasm, the 
RNase Dicer in complex with the double-stranded RNA-binding protein TRBP 
cleaves the pre-miRNA hairpin to its mature length. The functional strand of 
the mature miRNA is loaded together with Argonaute (Ago2) proteins into the 
RNA-induced silencing complex (RISC), wher  it guides RISC to silence target 
mRNAs through mRNA cleavage, translational repression or deadenylation, 
whereas the passenger strand (black) is degraded. In this review we discuss 
the many branches, crossroads and detours in miRNA processing that lead to 
the conclusion that many different ways exist to generate a mature miRNA.
Editing is defined as a post-transcriptional change of RNA sequences 
by deamination of adenosine (A) to inosine (I), altering the base-
pairing and structural properties of the transcript. Editing of miRNA 
transcripts by ADAR1 and ADAR2 was first described for miR-22 
(ref. 116) followed by miR-151, miR-197, miR-223, miR-376a, miR-
379 and miR-99a (ref. 117), as well as miR-142, miR-223, miR-1-1 
and miR-143 (ref. 118). In pri-miR-142, A-to-I editing inhibits its 
cleavage by the endonuclease Drosha and results in its degradation 
by the ribonuclease Tudor-SN, which preferentially cleaves double-
stranded RNA containing inosine–uracil pairs118,119. However, edit-
ing of other pri-miRNAs was shown to enhance their processing by 
Drosha120. Editing can also influence further downstream processing 
steps: pri-miR-151 editing abolishes its cleavage by Dicer in the cyto-
plasm. It remains to be established whether miRNA editing events 
are predominantly nuclear or cytoplasmic and whether they occur 
on the pri-miRNA or on the precursor miRNA (pre-miRNA)121. In 
addition to altering miRNA processing, miRNA editing can have 
an impact on miRNA target specificity. For example, a single A-to-I 
change in the miR-376 precursor redirects the mature miRNA to 
a new target, resulting in altered protein expression in mice122. In 
summary, miRNA editing can influence processing at multiple steps 
or can change the miRNA complementarity to target sequences, 
increasing the diversity of the cellular miRNA pool.




short hairpin RNAs (shRNAs) at the base of the stem loop, releasing an ~60–70 nt precursor 
miRNA (pre-miRNA) that contains a ~2-nt 3’ overhang. This structure serves as a signature 
motif that is recognized by the nuclear export factor EXPORTIN-5. Pre-miRNA complexes 
together with EXPORTIN-5 and its cofactor RAN (the GTP-bound form) to be exported to the 
cytoplasm (Yi et al., 2003). DICER cleaves ~22 nt from the Drosha cleavage site, thus 
generating ~22 nt duplex miRNA (with 2-nt 3’overhangs) (Hutvagner et al., 2001; Ketting et al., 
2001; Kim et al., 2005).  The duplex is separated and usually one strand is selected as the mature 
miRNA and the other strand is degraded. The guide strand of the miRNA remains associated 
with Ago2 and associated into the active RNA-induced silencing complex (RISC) (Hammond et 
al., 2000; Martinez et al., 2002). RISC identifies target messages based on complementarity 
between the guide RNA and the mRNA, and Ago2 and RISC lead to either the endonucleolytic 
cleavage of targeted mRNA or translational repression (see Intro figure 8) (Bartel, 2004; Gregory 
et al., 2005; Hannon, 2002; Lim et al., 2005). 
MiRNAs and the RNAi response are endogenous processes that have been 
experimentally hijacked to silence genes at will in mammalian cells (Paddison et al., 2002). The 
generation of shRNA-mir (short hairpin RNA-microRNA) libraries that cover nearly the whole 
human genome and enable the knock down of almost every gene in the human genome allow the 
functional interrogation of the whole genome (Silva et al., 2005; Silva et al., 2008). This shRNA-
mir library was based in the mir30-backbone (Lee et al., 2003; Lee et al., 2004), a backbone that 
has shown previous success in introducing RNAi into mammalian cells. The shRNA-mir library 
produces RNAi in a hairpin structure that mimics the pri-miRNA, the intermediate in the miRNA 




allows for better recognition of RNAi by RNAi machinery (Paddison et al., 2004; Silva et al., 
2005). 
 
Summary of research 
Here, we endeavored to identify a novel breast cancer tumor suppressor. To pursue this 
aim, we utilized the shRNA-mir library and microarray platform (Silva et al., 2005; Silva et al., 
2008) pioneered by our lab to do a genome-wide search for genes that modulate anoikis. We 
aimed to identify genes that when knocked down conferred an increased resistance to anoikis 
during an in vitro anoikis selection screen. Our anoikis selection screen provided a list of 194 
genes as potential modulators of anoikis. In search of genes that played a role in cancer and 
cancer suppression, we assessed which of these 194 genes were housed in chromosomal regions 
that are altered in primary tumors. To do this, we pioneered a GISTIC-like algorithim that is able 
to identify regions enriched in tumor suppressors ISAR_DEL. Between these two methods, we 
identified bridgingintegrator 3 (BIN3) as the top common hit, suggesting BIN3 as candidate 
tumor suppressor that may be able to modulate anoikis. BIN3 is at the epicenter of a ~300kb 
region that ISAR narrowed down from the commonly deleted 8p21.3-8p21.2 region. This region 
is altered in about 50% of breast cancers and is associated with poor prognosis characteristics in 
breast cancer patients. 
Here, we validated that loss of BIN3 confers anoikis resistance, and in turn, loss of BIN3 
increases the metastatic potential of breast cancer cells and increases primary growth of breast 
cancer tumors. The restoration of BIN3 decreases the tumorignecity of breast cancer cells and 




Mechanistically we have found that, BIN3 regulates P38α during detachment and anoikis 
signaling. During detachment, BIN3 complexes with TUBA, a CDC42-specific GEF and 
activator of CDC42, and BIN3 localizes TUBA to the membrane to activate CDC42. Loss of 
BIN3 leads to the mislocalization of TUBA at the membrane and decreases CDC42 activation.  
Loss of BIN3 attenuates the activation of P38α during detachment. Loss a BIN3 attenuates 
CDC42 activity and in turn attenuated P38-signaling during anoikis. 
 Our data implicate BIN3 as a tumor suppressor that is able to use its BAR domain to 
sense the high curvature of membranes of rounded, detached cells and BIN3 is able to lead 











Materials and Methods 
Real-time quantitative PCR (RTQ-PCR) 
Total RNA was extracted from cells according to manufacturer’s instruction using 




random primers. Reverse Transcription of RNA was performed as directed using TaqMan 
MicroRNA Reverse Trancription Kit (Applied Biosystems, 4366596) in a 20µl volume. cDNA 
was used for template for RTQ-PCR using FastStart SYBR Green Master (Roche, 04 673 492 
001). Reactions were performed in triplicate.  
Forward and reverse sequences were as follows: Human BIN3 5’- 
CTTACTCTCCAATCCCCTCT -3’and 5’- TCGATCACAGTCTTCTGGA-3’; Human GAPDH 
5’-CATCTTCTTTTGCGTCGC-3’ and 5’-AAAAGCAGCCCTGGTGAC-3’. 
PCR and PCR primers 
PCR was performed using FastStart Taq DNA Polymerase, dNTPack (Roche, 04 738 420 
001) as directed by manufacturer. Primers amplifying the shRNA library were diluted to 10µM. 
Forward and reverse sequences were as follows:  5’-TAGTGAAGCCACAGATGTA - 3’; and 
5’-TCTGTAATCCAGAGGTTGATTGTTCCA-3’. 
Primers amplifying genomic DNA were diluted to 40µM. Forward and reverse sequences 
were as follows: BIN3 Primer 1 5’- GGTAGCAGAGAAGTGTGAGC-3’ and 5’ 
ACTGAGAGTGTGTCCTCCAC-3’; BIN3 Primer 2 5’- TCCCCACTTCTCACAATATC-3’ and 
5’- GGAGGGGAGAAGCTAGTAAG-3’; BETA ACTIN Primer 5’-
GATGAGCTCTTTTTCTGGTG-3’ and 5’- AGCTTCTCCTTAATGTCACG-3’. 
Plasmids and shRNAs 
shRNAs against BIN3 
The following shRNAs against human BIN3 were bought from Thermo Scientific 




V3LHS_303350(shRNA #3), V2LHS_30167 (shRNA #4), V3LHS_400167 (shRNA #5). pGIPZ 
non-targeting control (RHS4346) was purchased from Thermo Scientific. 
Plasmids 
BIN3 expressing construct (PLOHS_100070502), RFP-positive control (OHS5832), and 
V5-tagged-BIN3 expressing plasmid (ccsbBroad304_12289) were bought from Thermo 
Scientific OpenBiosystem.  
Firefly Luciferase expressing construct (de Wet et al., 1987)was a gift form Jan 
Kitajewski (Columbia University, New York, New York).  
Constitutively active CDC42-Q61L (Subauste et al., 2000) (Addgene plasmid 12974), 
constitutively active RAC1-Q61L (Nobes and Hall, 1999)(Addgene plasmid 15903), 
constitutively active RHOA- Q63L (Nobes and Hall, 1999) (Addgene plasmid 12961) 
were purchased from Addgene. 
Constitutively active HER2 (Wang et al., 2006) was a gift from Senthil Muthuswamy 





MCF-10A-Triple Modified (MCF-10-TM) cell line (Pires et al., 2013) was a gift from 
Ramon Parsons (Mount Sinai School of Medicine, New York, New York) and was cultured in 
growth media: DMEM/F12 50/50 (Corning, 10-092-CV) supplemented with 5% horse serum 
(Invitrogen, 16050-122), 20ng ml-1 EGF (Sigma, E9644), 1ng ml-1 Cholera Toxin (Sigma, 
C8052), 10µg ml-1 insulin (Sigma, I9278), 100µg ml-1 Hydrocortisone (Sigma, H0396), 50 U ml-
1 Penicillin and 100µg ml-1 Streptomycin (Life Technologies, 15140-122). 
HCC38, HCC70, and MDA-MB-231 cell lines were purchased from ATCC. HCC38 and 
HCC70 were cultured in RPMI-1640 Medium (Sigma, R7388) supplemented with 10% fetal 
bovine serum (Invitrogen, 10082-147), 50 U ml-1 Penicillin and 100µg ml-1 Streptomycin (Life 
Technologies, 15140-122). MDA-MB-231 was cultured in Dulbecco’s Modified Eagle’s 
Medium (Sigma, D6429) supplemented with 10% FBS, 50 U ml-1 Penicillin and 100µg ml-1 
Streptomycin (Life Technologies, 15140-122). All cells were incubated at 37ºC and 5% CO2 in a 
humid atmosphere and cultured in sterile conditions. 
 Transfections 
Phoenix packing cells were a gift from Elena Ezhkova (Mount Sinai School of Medicine, 
New York, New York). Phoenix packaging cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (Sigma, D6429) supplemented with 10% FBS, 50 U ml-1 Penicillin, and 100µg ml-1 
Strep (Life Technologies, 15140-122). 6µg of DNA was transfected with either 3µg of lentiviral 
helpers, CMV and PMD (Salmon et al., 2000), or 3ug of retroviral helpers, VSV-G and ψ 
(Salmon et al., 2000), using 40µl Linear PEI (Polysciences , 24314) in a 100mm plate following 
manufacturer’s instructions. 




MCF-10A-TM cell line was infected with the shRNA-mir library (Silva et al., 2005) as 
previously described (Rodriguez-Barrueco et al., 2013). After selection with puromycin and four 
passages, 1.5x 106 cells ml-1 infected cells were mixed in equal portions with parental MCF-10A-
TM cells, the mixture was plated in triplicate in low-attachment flasks (Corning, 3814) for five 
days. After five days, the cells and media were collected from the flasks and centrifuged at 1200 
rpm-1 for 5 minute, resuspended, and plated in adherent tissue culture plates. Cells were allowed 
to adhere, recover, and to grow to nearly 80% confluency. Once nearly confluent, surviving cells 
were trypsinized and the percentage of GFP-containing cells were measured by FACS analyzer 
(LSRII Flow Cytomer, BD). Then, the cells were plated again in low-attachment plates and the 
process was repeated a total of three times. After the third quantification of the GFP-positive 
percentage, the anoikis-selected cells were plated in adherent plates and expanded. DNA from 
the infected cells before anoikis-selection and after the third round of anoikis selection was 
extracted and the representation of the shRNAs was compared as previously described (Paddison 
et al., 2004; Rodriguez-Barrueco et al., 2013). Genes with a >2-fold increased shRNA 
representation after anoikis selection were filtered. 
ISAR_DEL 
ISAR-DEL is a novel algorithm to detect regions of recurrent copy number alteration in 
cancer. It is based on the recently developed method ISAR [Reference Helios], which has been 
enhanced to better model regions of recurrent loss. The algorithm uses the G-score metric, a 
significance measure of the aberration for each marker, which was originally defined in GISTIC 
(Beroukhim et al., 2007). Specifically, the G-score for a marker m is the summation of the copy 
number across samples that surpass an aberration threshold θ. Therefore, given the copy number 











State of the art algorithms like GISTIC2 (Mermel et al., 2011) compute a null distribution across 
the entire genome to estimate the significance of the alterations harbored by each marker. 
However, the alteration rate can strongly differ cross genomic regions, due to features such as 
DNA secondary structure and DNA hypomethylation. ISAR accounts for local differences in the 
alteration rate due to these and other unknown forces by scoring the significance of each 
alteration locally. ISAR uses a local sliding window of constant size that moves along the 
chromosome, calculating the background distribution for each window. The use of a window 
allows the algorithm to estimate the local background distribution of alteration, which in turn is 
used to assign an accurate q-value to each marker based on the local background alteration 
frequencies.  
Because each type of alteration is characterized by a different background distribution, 
the significance of the gains and losses harbored by a gene needs to be estimated independently. 
ISAR-DEL exploits another key difference between gain and losses to identify drivers in deleted 
regions. Amplifications are generally expected to have a functional effect only if they span the 
whole sequence of a gene. However, this is not the case for deletions:  the loss of a fraction of 
the sequence of a gene is likely to cause its inactivation. For example, deletions encompassing 
portions of BRCA1 and PTEN have previously been observed as mechanisms to cause the 
inactivation of these tumor suppressors in different clinical tumors (Abdel-Rahman et al., 2006; 
van den Ouweland et al., 2009) Indeed, even the loss of a single base pair can render a key 




Given that inactivating aberrations in tumor suppressing driver genes are selected for in 
tumors and that those do not need to span the whole gene, such genes may display a pattern of 
non-overlapping deletions.  For example, Fig. 3a illustrates the recurrently deleted 10q23 region 
in the TCGA breast cancer dataset. The bona fide tumor suppressor PTEN stands out as the 
epicenter of this region due to a striking patter of losses of different parts of the gene: start, end, 
intragenic regions or the whole gene. An approach that considers the most altered marker would 
underestimate the significance of the aberrations harbored by this gene as many of these do not 
overlap. Considering all the accumulation of deletions along the entire gene, rather than 
accumulation at a specific locus, could aid distinguishing between driver and passenger genes in 
a deleted region. 
The input data for the algorithm consists of the copy number reads for genetic markers 
across the genome for a cohort of tumors. Each gene spans a set of genetic markers and we 
assume that the alteration of any of those markers would cause the inactivation of the gene in the 
same way that the full deletion of the gene would. Thus, the expected functional effect of the 
deletions harbored by a gene in a sample is determined by the strongest loss across all markers. 
For a gene g, we define the gene deletion G-score as: 
 !!"# ! = max
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That is, the G-score considers for each sample the most significant alteration across the M 
consecutive markers corresponding to the gene location.  
However, in order to calculate the significance of the alterations harbored by a gene one 




gene. Larger genes are more likely to be hit by passenger alterations, resulting in larger gene 
deletion G-scores. We therefore developed ISAR_DEL, a novel method that estimates the 
significance of the recurrence of all deletions accumulated by a gene. 
ISAR calculates de null distribution of G-scores by calculating the score for all possible 
permutations of markers belonging to the local window within each sample. Similarly to 
GISTIC, ISAR computes this estimate by performing the convolution of the histogram of values 
in each sample. Note that for a given gene size, the null distribution for the novel gene deletion 
G-score can be computed with the same permutation scheme used in the case of a single marker 
by simply substituting the copy number of each marker m with the minimum copy number 
across M consecutive markers starting in m. Unfortunately, estimating this null distribution for 
all gene sizes is unfeasible due to the high computational cost of this operation.  
ISAR_DEL avoids the computational burden of calculating the background distribution 
for all gene sizes by disregarding those that can be deemed unnecessary beforehand. We will 
show how the design of the ISAR method - specifically the fact that ISAR computes the 
background distribution in a local window - facilitates the optimization of the computational cost 
of the algorithm.  
For a given local window, ISAR only needs to consider the gene sizes corresponding to 
the genes located in the window. While this step already shrinks the number of genes sizes 
dramatically, further filtering is needed to reduce the computational cost of the algorithm. 
First, we discard most genes from considerations by using the background distribution as 
an upper bound on the significance of the recurrence of alterations. A simple way to produce 
such an upper bound is to compute the significance of the gene deletion G-score using a 




window ISAR_DEL calculates the background distribution for genes that span a single marker. 
Most genes will not be deemed statistically significant for this background distribution and can 
be therefore discarded, avoiding the computational cost of calculating the background 
distribution for their exact gene size. For example, in the TCGA breast cancer data, ~85% of the 
genes were discarded by this step.   
Second, we make use of the fact that ISAR uses a sliding window that selects for each 
gene the least significant score across overlapping windows. If the alterations harbored by a gene 
were deemed statistically insignificant in a window it is unnecessary to further consider this gene 
in any subsequent window. 
Third, we can further improve the computational time by further approximation. 
Specifically, we can bin similarly sized genes and can consider the same background distribution 
for this group of genes. Taking into account that gene sizes follow an exponential distribution, 
this can significantly reduce the number of required calculations. The user-defined parameter 
delbin defines a bin size for a binning scheme. A conservative approach is employed in this 
approximation, using the largest gene size in the bin to compute the background distribution for 
the bin.  
We used ISAR_DEL to analyze the deletion landscape of 785 breast cancer samples 
collected by the TCGA project using Affymetrix 6.0 SNP arrays (TCGA, 2012). ISAR_DEL was 
executed using the same parameters as in [Reference Helios] and delbin=1 (no approximation for 
gene size). Compared to the 4 hours that ISAR needed to analyze the data, ISAR-DEL had a total 
execution time of 11 hours in a laptop equipped with an Intel i7-2620M 2.7GHz processor and 8 
GB of RAM. Figure 1e shows the results of applying the algorithm to the 10q23 region. 




with the second most altered gene, KILLIN, is quite small. Indeed, GISTIC2 is unable to 
distinguish which of the two genes is the target of the region and both genes are selected in the 
peak region. However, when all the alterations harbored by each gene are considered, the 
difference between the S-score of the two genes increases dramatically as we can see in Figure 
3a. In the 13q14 region if the best marker is considered RCBTB2 is the top scoring gene but 
once all alterations harbored by each gene are considered, the well-known tumor suppressor RB1 
clearly becomes the top-scoring gene. 
We selected those genes whose enhanced gene S-score was both larger than the threshold 
and the marker-based S-score. Fig. 3b shows the 4 genes that comply with these criteria. Three 
of these genes are bona fide tumor suppressors (MAP2K4, RB1, PTEN) while the fourth gene is 
BIN3. All of these genes had the most significant S-score in their respective regions once the 
enhanced gene S-score was considered. Indeed, BIN3, similarly to the case of RB1, only 
becomes the most significant gene once the enhanced gene S-score is considered Figure 4. 
GISTIC2, the state of the art algorithm for the identification of regions of recurrent CNA used by 
the TCGA, also provides the option of calculating a gene-based score based on all the alterations 
that target a gene. GISTIC2 detects regions containing the four genes with RB1, PTEN and 
MAP2K4 as top of their regions. However, BIN3 is selected a part of a large deletion covering 
the span of 15 Mbp (chr8:20154149-35523298), where it is the 64th candidate (Cancer Genome 
Atlas, 2012). Hence the sensitivity of ISAR-del was crucial in identifying BIN3 as a potential 
tumor suppressor from primary samples.  





Anoikis assays were performed with a cell concentration of 1 x105cells ml-1. BIN3 Knock 
down (GFP-positive) and BIN3 cDNA Re-expressing cells (GFP-positive) expressing and their 
respective controls (also GFP-positive or RFP-positive respectively) were mixed in equal 
amounts with parental (GFP and RFP-negative) cells and plated in low-attachment plates 
(Costar, 3471) and cultured in growth media. Media and cells were collected, centrifuged at 1500 
rpm-1 for 5 minutes, resuspended in PBS, and analyzed by FACS analyzer (LSRII Flow 
Cytomer, BD).  
-Individual Anoikis Assay 
Anoikis assays were performed with a cell concentration of 1 x105 cells ml-1. Cells 
variants were plated in duplicate in low-attachment plates (Costar, 3473) and cultured in growth 
media. Cells were collected and centrifuged at 1500 rpm-1 for 5 minutes and resuspended in the 
CellTiter-Glo Substrate Reagent from the CellTiter-Glo Cell Viability Kit (Promega, G7571), 
prepared as instructed by manufacturer. Luminescence was read by a luminometer (Modulus II 
Microplate Reader, Turner Biosystems).  
-Soft agar colony formation assay 
Cells were plated in semi-solid media as follows: 35mm plates were layered with 0.6% 
agar (Spectrum Chemical, AG110) and media, cells were seeded in triplicate in the second layer 
of 0.3% agar and media, and cultured in appropriate growth media. Cells were plated in the 
following concentration: 5.0 x103 cells ml-1MCF-10A-TM-Non Targeting cells and -BIN3KD 
cells (MCF-10A-TM-Variants), 5x103 cells ml-1 HCC70-Control and -BIN3cDNA cells 




Colonies were stained with 1mg/ml MTT (Sigma, M2128) after three weeks of incubation, 
photographed, counted, and the average + standard deviation was represented.  
-CDC42 Activity measurement 
The amount of CDC42-GTP and activation of CDC42 was measured using G-Lisa 
CDC42 Activation Assay Biochem Kit (Cytoskeleton, BK127) following the manufacturer’s 
instructions for adherent and non-adherent cells with the following additions: after being plated 
for 2 days in adherent plates, cells were trypsinized when they reached a confluency of about 30-
40% and plated in triplicate in low attachment plates at 1x 105cells ml-1.  At appropriate time 
points, media and cells were collected, centrifuged at 4°C at 6000 x g for 2 minutes, media was 
aspirated, cells were washed in cold PBS, centrifuged again at 4°C at 6000 x g for 2 minutes, 
snap frozen in liquid nitrogen, and stored at -80°C until use. A concentration of 0.50mg ml-1 of 
total protein was used for the assay. 
-Proliferation Assays 
5 x 102 cells ml-1 of MCF-10A-TM-Variants and HCC38-Variants were seeded in 96-well black 
plates (Costar, 3603) in triplicate.  Cells were incubated the CellTiter-Glo Substrate Reagent 
(CellTiter-Glo Cell Viability Kit, Promega, G7571), and incubated in the dark at 37ºC for 10 
minutes. Luminescence was read by luminometer (Modulus II Microplate Reader, Turner 
Biosystems). 
Fractionation 
 Cell fractionation was performed using manufacturer’s instructions (Calbiochem, 
539790). 2 x106 MCF10A-TM-Variants were plated in low-attachment plates (Costar, 3471) for 




MCF10A-TM-Variants were plated in normal 35mm plates for 24 hours and treated as adherent 
cells in the protocol. Proportional and equal amounts were loaded for immunoblot analysis. 
Western Blot and Immunoblot 
Cells were lysed in EZ Buffer (60mM Tris pH7, 10% 1M DTT, 10% glygerol, 2%SDS, 
1mM Sodium orthovanadate (Sigma, S6508)). Protein lysates were boiled at 90ºC for ten 
minutes and 40µg of total protein was separated by SDS-PAGE gels and transferred to 
polyvinylidene fluoride membrane (Life Sciences, 66542). Non-specific binding was blocked by 
incubation with 5% of non-fat milk and TBST (20 mM Tris-Hcl pH7.4, 150 mM NaCl, 0.1% 
Tween-20). Membranes were incubated with the primary antibodies overnight at 4ºC and by 
appropriate secondary antibody incubation for an hour at room temperature.  
Antibodies used for immunoblot in this study were directed against BIN3 (Origene, 
TA501966), P38α (Cell Signaling, 9218), phospho-P38 (T180/Y182, Cell Signaling, 9211), 
CDC42 (Santa cruz, sc-87), BIM (all isoforms, Cell Signaling, 2933), phospho-BIM (Ser69, Cell 
Singaling, 4581), phospho-ERK 1/2 (Cell Signaling, 4370), BETA-ACTIN (US Biological, 
A0760-40), EGF Receptor (Cell Signaling, 2232), HISTONE H3 (abcam, ab1791), TUBULIN 
(abcam, ab6161), TUBA (Proteintech, 17191-1-AP). Anti-Mouse (NA931V), anti-Rabbit 
(NA934V), anti-Rat (NA9350V) horseradish peroxidase-conjugated antibodies from GE 
Healthcare were used. 
Anoikis assays for immunoblot analysis 
MCF-10A-TM-Variants were plated 1x106 cells ml-1 in low- attachment plates. HCC38–
Variants were plated 1 x105 cells ml-1. Media and cells was collected and centrifuged at 1500 
rpm-1 for 5 minutes, resuspended in PBS, centrifuged again, and then resuspended in lysis buffer 




CDC42 Activator and CDC42 Inhibitor 
RHO (CDC42/RHOA/RAC1) Activator I was bought from Cytoskeleton (CN04). 
CDC42 inhibitor, ML141 (SML0407) was purchased from Sigma-Aldrich. Cells were plated 
(for immunoblot 1x 106 cells ml-1 or for individual anoikis assay 1 x105 ml-1) and treated at 
concentration with 1µg/ml of RHO Activator I or 10µM of CDC42 inhibitor in growth media. 
Cells were either lysed for immunoblot or cell viability was analyzed as previously described. 
Immunoflouresence 
6.0 x 104 cells ml-1 MCF10A-TM-V5-tagged BIN3 cells were plated in chamber slides 
(Lab-Tek, 177402) for 24 hours.  1x106 cell ml-1 MCF10A-TM-V5-tagged BIN3 cells were 
plated in low-attachment plates (Costar, 3473) for 24 hours. After 24 hours, cells and media 
were then collected from low-attachment plates, centrifuged at 1500rpm-1 for five minutes, 
resuspended in trypsin, incubated for ten minutes at 37°C, centrifuged again, resuspended in 
growth media, and 1.2 x 105 cells ml-1 were plated in chamber slides (Lab-Tek, 177402) for an 
hour and half. All cells were fixed with 4% Paraformaldehyde for ten minutes at room 
temperature. Following PBS washes, cells were permebealized with 0.5% PBS/Triton for ten 
minutes at room temperature.  Excess PBS/Triton was removed with PBS washes and slides 
were blocked using 10% Goat Serum (MP Biomedicals, 55984) in 2% BSA/PBS for an hour at 
room temperature.  Primary antibodies were incubated overnight at 4°C.  Slides were incubated 
with appropriate secondary antibodies for an hour in the dark.  Finally, slides were mounted 
with Vectashield Mounting Medium with DAPI (Vector Labs, H-1200).   
Antibodies used for immunoflouresence anti-V5 (Life Technologies, 46-0705), CDC42 




Secondary antibodies used were Alexa Fluor 594 (Invitrogen, A11032) and Alexa Fluor 488 
(Invitrogen, A11034). 
Immunoprecipitation 
2.0x107 MCF-10A-TM cells stably expressing V5-tagged-BIN3, MCF-10A-TM-
BIN3KD, and MCF-10A-TM-Non-targeting cells were plated in adherent plates and in low-
attachment plates (Corning, 3814) for 24 hours. Afterwards, cells were lysed with 1mL of lysis 
buffer (140mM NaCl, 10mM EDTA, 10% glycerol, 1% NP40, 20mM Tris pH8.0 supplemented 
with 1x protease inhibitors (Roche, 04693159001), 1mM ortovanadate, 1mM sodium fluoride, 
and 1mM phenylmethylsulfonyl fluoride) for an hour at 4ºC on a rotator. 
Protein concentrations were determined using the Protein-G Assay Kit (Bio-Rad, 500-
0006). 1mg of protein extract was pre-cleared with G agarose beads (Roche, 11719416001) for 
an hour at 4ºC on a rotator. Sample and beads were centrifuged at 4ºC for 5 minutes. Afterwards, 
protein extract was recovered and beads were discarded. The supernatant fraction was used for 
Immunoprecipitations (IP). IPs were performed by mixing1mg of protein extract (supernatant) 
with 2µg of antibody and incubated overnight at 4ºC. 
After 24 hours, extracts were washed three times with lysis buffer and beads were finally 
resuspended in EZ lysis buffer (1M Tris pH7, 50% glycerol, 20% SDS, 1mM ortovanadate, 
1mM sodium fluoride and 1mM phenylmethylsulfonyl fluoride). Equal amounts were loaded for 
immunoblot analysis. 
Antibodies used for IP were anti-V5 (Life Technologies, 46-0705) and control non-
immunized anti-mouse IgG (Santa Cruz, sc-2025). 
Antibodies used for Immunoblot were TUBA (Proteintech, 17191-1-AP) and anti-V5 




In vivo experiments 
-Mammary fat pad transplantation 
MCF-10A-TM-Variants were transplanted as previously described (Deome et al., 1959) 
into the mammary fat pads of NOD SCID immunocompromised mice NOD.CB17-Prkdcs SCID 
mice (Harlan) at concentration of 1x 107 cells per a mammary fat pad. HCC38, HCC70 variants 
were transplanted in to SCID mice at cell concentrations of 5x106 cells per a mammary fat pad. 
MDA-MB-231 variants were transplanted at cell concentration of 1x106 cells per a mammary fat 
pad. 
-In vivo cell detachment assay 
MCF-10A-TM-Variants, MDA-MB-231-Variants, and HCC38-Variants were engineered 
to express firefly luciferase. 5 x105 cells 100µl-1 of MCF-10A-TM-Variants and MDA-MB-231-
Variants, and 2.5 x 106 100µl-1 of HC38-Variants were intravenously injected into the tails of 
NOD SCID immunocompromised mice NOD.CB17-Prkdcs SCID mice (Harlan) as previously 
described (Elkin and Vlodavsky, 2001). IVIS Spectrum Pre-clinical In Vivo Imaging System 
(PerkinElmer, IVISSPE) machine was used to assess luciferase intensity. To check the luciferase 
intensity of injected cells, 2.25µg ml-1 lucifern was injected intravenously through the tail and 
luciferase activity was assessed 5 minutes after luciferin injection.  
Patient databases 
Patient data were assessed from cBioPortal (http://www.cbioportal.org/public-portal/ ), Metabric 












 Genetic screen and algorithm identify BIN3 candidate tumor suppressor that modulates of 
the anoikis response 
!
As a first step to identify novel breast cancer TS, we performed a shRNA screen designed 
to uncover genes that positively modulate anoikis (Fig. 1a). A pooled lentiviral library of 58,493 
unique shRNA-mirs (Silva et al., 2005) targeting 18652 known human genes was used to infect a 
variant of the non-transformed cell line, MCF-10A; a human mammary epithelial cell line that 
has been classically used as model to study anoikis (Marani et al., 2004). Because MCF-10A 
cells are highly sensitive to detachment and almost all cells die rapidly when attachment is 
prevented by plating cells in low-attachment culture plates (Fig. 1b), we used a MCF-10A 
variant engineered to carry the three most common alterations of triple negative breast cancers 
(PTEN loss, inactivation of TP53 by a dominant negative mutation, and the overexpression of 
EGFR (Pires et al., 2013) to augment the sensitivity to detect genes that modulate anoikis. This 
MCF-10A variant is not tumorigenic, but has a moderate intrinsic resistance to anoikis (∼20%!
survive after 5 days in suspension) and, importantly, can become more resistant by additional 
genetic alterations (Fig. 1b). In this manuscript, we will call this variant MCF-10A-Triple 
Modified (MCF-10A-TM). Our shRNA backbone vector co-expresses the targeting shRNA-mir, 




infected with the shRNA-mir library were puromycin selected and then mixed at a 1:1 ratio with 
parental MCF-10A-TM cells (anoikis competition assay). These cells were then plated in low-
attachment plates for 5 days. After that time, the surviving cells were recovered and plated in 
normal culture conditions for a week. By quantifying the proportion of cells that expressed the 
green fluorescent marker within the mix, we were able to track and distinguish the shRNAs 
library-infected population. If the population that expressed the shRNA library and the green 
fluorescent marker had a survival advantage, the green population would eventually predominate 
in the mix. After three rounds of the anoikis competition assay, we saw that almost all cells in the 
surviving population expressed the green marker (Fig. 2b), suggesting that the library conferred a 
survival advantage. 
Next, we identified the shRNAs that were enriched in the surviving anoikis resistant cells by 
using customized microarrays as we have previously described (Silva et al., 2008). Not 
surprisingly, David pathway analysis revealed that the most enriched shRNAs (4FC and 
FDR<0.1), were shRNAs that targeted genes involved in intrinsic and extrinsic apoptotic 
signaling (Fig. 1a). In fact, Capase-8 was the top hit in our screen. 
Our anoikis screen resulted in a large number of shRNAs that were enriched after anoikis-
selection, implicating their cognate gene as potential modulator of anoikis.  Therefore to filter 
this list and identify potential tumor suppressor genes, we used a complementary source of data, 
a primary breast cancer cohort collected by the (The Cancer Genome Atlas) TCGA (Cancer 
Genome Atlas, 2012) developed a novel computational method, ISAR-DEL that specifically 
aims to pinpoint candidate tumor suppressor genes based on recurrent loss of copy number (see 
Material and Methods). The benefits of integrating functional screens with primary tumor data 




characterizes pooled genome-wide functional screens. Second, by selecting candidates from 
primary tumors, we prioritize genes that have clinical relevance. Third, the functional data allows 
us to associate a phenotype, in this case anoikis, with the genetic data. 
ISAR-DEL is based on the intuition that copy number deletions typically serve to inactive the 
tumor suppressor and can therefore we expect copy number loss to target multiple loci along the 
gene.  Therefore, to maximize the selectivity in regions of loss, we take into account the 
contribution of all deletions harbored by a gene, rather than focusing on each locus 
independently (Fig. 3a).  ISAR-DEL identified four genes, each in recurrently deleted regions, 
that when the pattern of partial deletions was included, the score of these genes was substantially 
improved; this allowed these genes to rise to be the top scoring genes of their respective regions. 
These genes included 3 bona fide tumor suppressors (PTEN, RB1, and MAP2K4) (Fig. 3b). The 
fourth gene, BIN3, scored as top candidate tumor suppressor in the commonly deleted 8p21 










Results Figure.1. Schematic representation of shRNAi screen and survival during 
detachment of MCF-10A variants. (a) Graphic representation of the genetics-genomics 
strategy described in the text. The table shows the most significant pathways enriched in our 
shRNA anoikis screen. (b.) Percentage of viable cells (survival) of MCF-10A cell variants 
plated in suspension over 5 days. Percentage compared to viability on day of plating (Day 0). 
MCF-10A= Parental; MCF-10A-TM (MCF-10A-Triple Modified as described in the main 
text); MCF-10A-TM-HER2=MCF-10A-TM overexpressing a constitutively activate form of 












Results Figure.2. shRNA-mir construct and anoikis enrichment screen.  (a.) Structure of 
the shRNA library used in the RNAi screen. (b). The upper part of the cartoon illustrates the 
design of the multiple rounds of anoikis in the shRNA screen. The lower part of the cartoon 
shows the enrichment of cells expressing shRNAs (green cells or GFP positive), measured by 
FACS analyzer, when a 1:1 mix of parental and cells transduced with the shRNA library as 









Results Figure 3. ISAR identifies most commonly deleted genes. (a) Copy number profile 
for the 10q23 region and ISAR scores for the genes in the region. PTEN deletions that do not 
span the whole gene are highlighted. The S-score improves once all deletions harbored by 
each gene are considered (gene S-score delta) clearly pinpoints PTEN as target of the region 










Results Figure 4. ISAR identifies BIN3 as top putative tumor suppressor candidate. 
Copy number profile of chromosome 8 highlighting the highly deleted 8p21 region and ISAR 
scores for the genes in the region. BIN3 becomes the top scoring candidate once all deletions 
targeting each gene are accounted. Selected samples showing partial deletions in the BIN3 





BIN3 is located on the chromosomal region 8p21.3, one of the most frequently lost 
regions in epithelial cancers and that is thought to contain several tumor suppressor (Anbazhagan 
et al., 1998; Chang et al., 2007; Rubio-Moscardo et al., 2005; Venter et al., 2005; Ye et al., 2007; 
Yokota et al., 1999). Specific analysis of the CNV for BIN3 in The Cancer Genome Atlas 
(TCGA) data sets (http://cancergenome.nih.gov/) shows that there is about 50% heterozygous 
(Ht) and homozygous (Ho) loss of the BIN3 locus in ovarian and breast cancers (Fig. 5a).  
Next, we focused our studies specifically on breast cancers and analyzed two data sets, 
TCGA and METABRIC!(Curtis et al., 2012); together these two data sets contained clinical and 
molecular information for about 3,000 breast primary tumors. These studies showed that BIN3 
expression is strongly driven by CNV (Fig. 5b) and that loss of BIN3 gene is associated with 
poor prognosis characteristics, such as high pathological grade, high stage, and increased 
probability of lymph node infiltration (Fig. 6a and b). BIN3 is lost at comparable levels in the 
most relevant breast cancer clinical subtypes (hormone receptor positive (HR+), triple negative 
(TNT), and HER2+) (Fig. 7a). Importantly, loss of BIN3 has a significant impact on the survival 
in all the groups except in HER2+ patients (Fig. 7b). Loss-of-expression of BIN3 enhances 




BIN3 is commonly deleted in epithelial malignancies and correlated with poor prognosis 







Results Figure 5. BIN3 Loss in breast cancer. (a) Percentage of BIN3 deletion in human 
cancers (data from TCGA). (b) Loss of the BIN3 locus strongly correlates with reduced 









Results Figure 6. BIN3 Loss is associated with poor prognosis characteristics. (a) Both 
deletion of BIN3 locus and reduced expression of BIN3 mRNA correlate with higher grades, 
higher stage (data from Metabric and TCGA) and (b) lymph node metastases p=.01 by chi 


















Results Figure 7. BIN3 Loss is associated with poor prognosis characteristics. (a) Two 
large series of primary breast cancers (TCGA and METABRIC) were classified in the most 
relevant clinical subtypes Triple Negative (TN), Hormone Receptor positive (HR+), and 
HER2 positive (HER2+) and the percentage of BIN3 loss was investigated. (b) Effect of BIN3 






Knock down of BIN3 increases tumorigencity  
All the above data suggests BIN3 as putative TS in breast cancers; consequently, we 
decided to individually validate the impact of its loss during tumorigenesis. First, we selected a 
series of shRNAs targeting BIN3. This series included shRNAs that were enriched in our pooled 
screen  (shRNA#4) as well as new ones (Fig. 8a). This series was used to knock down BIN3 in 
MCF-10A-TM cells. As expected, efficient silencing of BIN3 increased cell survival when 
attachment was prevented as demonstrated by the quantification of the absolute number of 
surviving cells (Fig. 8b) as well as by anoikis competition assay (Fig. 8c). Additionally, knock 
down of BIN3 also enhanced the ability of MCF-10A-TM cells to form colonies in semisolid 
media (Fig. 9a). 
Next, we transitioned our studies in vivo. When breast cancer cells are injected 
intravenously into the tails of recipient mice, the cells travel through the circulatory system and 
are deposited in the lungs. There, the majority of the cells die due to the lack of proper 
microenvironment, including lack of proper ECM attachment. We engineered MCF-10A-TM-
Control and -BIN3 knock-down cells to express a luciferase reporter gene and followed the fate 
of these cell lines after intravenous tail injection into SCID mice. Control cells rapidly cleared 
within ∼24 hours, while the knockdown of BIN3 allowed the cells to survive for a significantly 
longer period of time (Fig. 9b). Despite having a survival advantage, MCF-10A-TM-BIN3 
knocked down cells were not tumorigenic and were unable to form lung metastases (data not 
shown).  
     Thus, we turned our experiments to MDA-MB-231 cells; a breast cancer cell line that does 
not present deletion of the BIN3 locus (Figure 11a), expresses BIN3 protein (Fig. 10a), and is 




MDA-MB-231 cells were engineered with luciferase and injected intravenously into the tails of 
SCID immunocompromised mice. The cells transported to the lung and quickly cleared. 
However, in control cells, lung metastases were detectable about four weeks after injection. 
Importantly, silencing BIN3 in MDA-MB-231 cells enhanced lung metastases formation and we 
were able to detect luciferase signal in the lungs as soon as one week after injection (Fig. 10a). 
As expected, after sacrificing the mice, we noted the presence of many more metastatic colonies 
in the lungs of the mice that had BIN3 knock down cells injected. Since loss of BIN3 was 
detected in our genomic studies in primary human tumors, we assessed the effect of BIN3 loss on 
tumor growth. Thus, we orthotopically transplanted MDA-MB-231 cells into the mammary 
fatpads of SCID mice and followed the growth of the tumors. These experiments showed that 
BIN3 knock down cells generated significantly bigger tumors than wild type counterparts (Fig. 
10b). Interestingly, BIN3 knocked-down cells cultured in vitro did not showed any growth 



























Results Figure 8. Knock down of BIN3 promotes anoikis resistance. (a) shRNAs knock down 
of BIN3 mRNA and protein in MCF10A-TM cells. mRNA normalized to Non-targeting control. 
Silencing of BIN3 promotes resistance of MCF-10A-TM cells to detachment as shown by (b) 
total cell number (measured by cell viability and luminescence over 5 days in suspension) and (c) 
competition assays (measured by proportion of green cells over 6 days in suspension). 
Normalized to (a) total number of cells or (b) proportion of green cells on day zero. In all panels 











































Results Figure 9. Knock down of BIN3 promotes anchorage-independent growth and anoikis 
resistance in vivo. (a) Silencing of BIN3 promotes resistance of MCF-10A-TM promotes ability of 
MCF-10-TM to form colonies in agar. Variants were plated in semisolid media for 21 days and 
stained with MTT. (b) Silencing of BIN3 in MCF-10A-TM cells enhances survival after tail vein 
injection in SCID mice recipient mice. MCF-10A-TM cells were injected intravenously through the 
tails into SCID mice and luciferase intensity was measured over 36 hours. Luciferase intensity was 



































Figure 10. Knock down of BIN3 
promotes metastasis and primary 
tumor growth. Silencing of BIN3 in 
MDA-MB-231 enhances (a) the ability to 
form lung metastases after vein tail 
injection. MDA-MB-231 variants were 
injected intravenously through the tails 
of SCID mice. Luciferase intensity was 
measured over 56 days. On Day 56, mice 
were scarified and lungs of mice were 
analyzed for metastases.  Silencing of 
BIN3 in MDA-MB-231 enhances (b) 
growth of primary tumors after 
orthotopic transplantation in the 
mammary fatpad of SCID mice. Mice 
were sacrificed at 8 weeks and tumors 
were measured. (c) Growth curve study 
showing that silencing of BIN3 does not 
modify the growth of MCF-10A-TM 
cells in tissue culture as demonstrated by 
the total number of cells over 4 days. 
Total number of cells was determined by 









Restoration of BIN3 expression attenuates resistance to anoikis and tumorigenesis 
To further demonstrate the role of BIN3 in modulating the response to anoikis and tumor 
suppression, we restored BIN3 expression in breast cancer cells with homozygous deletion of the 
BIN3 locus. We took advantage of a large collection of cancer cell lines with publically available 
CNV and expression microarray data (Barretina et al., 2012). In this collection, out of 38 breast 
cancer cell lines analyzed, 15 (39.5%) had heterozygous deletion of the BIN3 locus, while 3 
(7.9%) had homozygous deletion (Fig. 11a). CNV and the expression data for BIN3 in seven 
breast cancer cell lines including cell lines suspected to have homozygous deletions (Ho) of the 
BIN3 locus are indicated in red and the length of the deletion in HCC-70 and HCC-38 (Fig. 11b). 
Competitive PCR using oligos for the BIN3 and the β-ACTIN genomic loci confirmed the 
homozygous loss that was detected by the microarray in two selected cell lines, HCC-38 and 
HCC-70 (Fig. 11c). As expected, BIN3 protein was undetectable in these cells (Fig. 12a).  
Restoration of BIN3 expression in HCC-38 and HCC-70 by lentiviral delivery of a cDNA 
construct enhanced the sensitivity to detachment (Fig. 12b and c) and reduced the ability of these 
cell lines to form colonies in semisolid media (Fig. 13a). Finally, we intravenously injected 
HCC-38 variant cells expressing luciferase into the tails of recipient mice. Here, cells re-
expressing BIN3 protein cleared from the lungs significantly faster that control counterparts (Fig. 
13b). Unfortunately, parental cells were unable to generate lung metastasis, which prevented us 
from studying the impact of BIN3 restoration in colonization and metastases in this organ.  
Notably, re-expression of BIN3 in both HCC-38 and HCC-70 cells reduced primary tumor 
formation and growth when these cell lines were transplanted orthotopically (Fig. 14a). Re-

















Results Figure 11. Deletion of BIN3 locus in breast cancer cell lines. (a) A large series of 38 
breast cancer cell lines with available CNV data was evaluated to identify cell lines with Ho deletion 
of BIN3. (b) The upper panel shows the CNV and the expression data for BIN3 in seven breast cancer 
cell lines (cell lines with homozygous deletions (Ho) are indicated in red). The lower panel shows the 
length of the deletion in HCC-70 and HCC-38. (c) Competitive genomic PCR validating the Ho 















































Figure 12 Restoration of BIN3 expression reduces anoikis resistance. (a) Western blots 
demonstrating the absence of BIN3 protein expression in cell lines with Ho deletions. 
Restoration of BIN3 expression reduces cell survival during anoikis as shown by (b) 
competition assay (measured by proportion of green cells over 9 days in suspension) and (c) 
total number of cells (measured by cell viability and luminescene over 5 days in suspension). 
Normalized to (b) proportion of fluorescent cells on day zero or (c) to total number of cells 















































Figure 13 Restoration of BIN3 expression reduces anchorage-independent growth and 
reduces anoikis resistance in vivo. (a) Restoration of BIN3 expression reduces cell ability of 
cells to produce colonies in soft agar. HCC-38 and HCC-70 variants were plated in semisolid 
media for 21 days and stained with MTT. (b) Restoration of BIN3 expression reduces cell 
ability to survive after tail vein injection in SCID mice. HCC-38 variants cells were injected 
intravenously through the tails into SCID mice and luciferase intensity was measured over 24 
hours. Luciferase intensity was compared to intensity an hour after injection.  In all panels the 




















Results Figure 14. Restoration of BIN3 expression reduces primary tumor growth. Growth 
curve study showing that re-expression of BIN3 does not modify the growth of HCC-38 cells in 
tissue culture as demonstrated by the total number of cells over 5 days. Total number of cells was 
determined by luminescence compared to Day 1 after plating. Restoration of BIN3 reduces 
ability to grow primary tumors after orthotopic transplantation in the mammary fatpad of SCID 







BIN3 connects loss of attachment with activation of the p38 stress signaling 
Our genetic data demonstrated the role of BIN3 as tumor suppressor. Next, we explored 
the mechanism that underlies the function of BIN3. For this analysis, we utilized the reverse 
phase protein array data (RPPA) available from cBioPortal software and analytical tools!(Cerami 
et al., 2012), which utilizes TCGA breast cancer data set. These studies provided quantitative 
information regarding the protein expression levels and phosphorylation status of ~200 proteins. 
Here, we found that BIN3 loss (Ho and Ht) was associated with tumors with enhanced 
translation, as exemplified by the significant association with loss of BIN3 locus and higher 
levels of phosphorylation (inactivation) of the translation inhibitory factor EIF4EBP1 (Fig. 15a) 
and mutations in Tp53. 
Importantly, in BIN3 deleted tumors, there were significantly lower levels of activation 
(phosphorylation) of MAPK14/p38-α protein. Importantly, P38-α has been shown to be a 
positive modulator and regulator of the anoikis response by inducing the stabilization and 
upregulation of the apoptotic facilitator BimEL (Wen et al., 2011). To validate the involvement 
of BIN3 in the activation of P38-α we compared the phosphorylation levels of P38-α in control 
and BIN3 knock down cells during detachment. As previously shown, plating MCF-10A cells in 
low-attachment conditions induced strong phosphorylation of P38-α and increased the total 
levels of BimEL (Fig. 15b). Remarkably, the expression of BIN3 was strongly upregulated upon 
detachment (Fig. 15b). 
In contrast, BIN3 knock down cells showed a very mild activation of P38-α and low 
accumulation of BimEL. Notably, there was also less activation of the P38-α/BIMEL axis 
observed in BIN3 knock down in the tumors generated by orthotopic transplantation of MDA-




the locus increased the activation levels of P38-α upon detachment and increased the levels of 
BimEL in vitro (Fig. 16a) and in primary tumors generated after orthotopic transplantation of 
these cells in the mammary fatpad of SCID mice (Fig. 16b).   
Genetic and biochemical approaches have shown that the fission yeast ortholog of human 
BIN3 (hob3p) regulates the activity of the small GTPase cdc42p by forming a complex with 
guanine nucleotide exchange factor gef1p (Coll et al., 2007) activator of cdcd42p. This 
regulation of CDC42 activity has been recently described to be conserved in mammals 
(Simionescu-Bankston et al., 2013). Since P38 is a known downstream effector of CDC42 during 
stress (Seo et al., 2004; Chan et al., 2008), including stress caused by the disruption of 
attachment (Bourdoulous et al., 1998) these data suggest a model in which BIN3 is able to detect 
detachment due to its ability to sense changes in the structure of the cell membrane, then assist in 
the activation of CDC42 by bringing its GEF activator, which in turns transmit the stress signal 
to P38α (Fig. 16c). 
To test our model we first studied the localization of these proteins upon detachment 
from the ECM. Cell fractionation experiments (Fig. 17a) together with immunofluorescence  
studies (Fig. 17b) showed that while cells are attached BIN3, TUBA (the human homolog of 
gef1p), and CDC42 are found independently in the cytoplasm of attached cells. However, a 
significant fraction of these proteins colocalized at the cell membrane when attachment was 
prevented. Next we performed immunoprecipitation (IP) of V5-tagged-BIN3 in MCF-10A-TM 
cells to demonstrate that in mammary epithelial cells BIN3 and TUBA are easily detected by co-
IP after cell detachment (Fig. 18a), which suggest that they form a complex. We were not able to 
Co-IP endogenous CDC42 together with BIN3-V5. This result is not surprising, as it has been 




the presence of CDC42 in the complex seems more unstable (Coll et al., 2007). When BIN3 was 
knocked down in cells, TUBA relocation to the cell membrane was significantly reduced (Fig. 
18b and 218c). Finally, we study the activation level of CDC42 (CDC42 bound to GTP) after 
cells are exposed to anoikis conditions. These studies showed that while CDC42 is activated 
during detachment the absence of BIN3 prevented its activation (Fig. 18d). 
Thus, we reasoned that if CDC42 function was compromised during detachment by the 
absence of BIN3, then experimental activation of CDC42 should restore the anoikis response. 
This was the case, addition of Rho activator-I (R.A.), a compound that activates Rho family 
members including CDC42, was able restore the activation of p38-α and reverse the resistance to 
anoikis of MCF-10A-TM Bin3 knock-down cells (Fig. 19a). To complete our studies, we used a 
specific inhibitor of CDC42 (ML-141). Treating MCF-10A-TM with this compound  
significantly inhibited both the activation of p38-α and the loss of cell viability induced when 










































Results Figure 15. BIN3 loss inhibits activation of 
P38α. (a) Table shows the most differentially 
expressed or activated proteins between primary breast 
cancers with loss (Ho and Ht) of BIN3 locus and breast 
cancers with diploid dose of the locus when RPPA data 
from TCGA were analyzed. (b) Western blots showing 
that silencing BIN3 blocks the activation 
(phosphorylation) of P38-α and the induction of the 
apoptosis facilitator BIMEL when cells are exposed to 
anoikis in vitro (24 hours detached). (c) Western blots 
showing that silencing BIN3 blocks the activation 
(phosphorylation) of P38-α and the induction of the 
apoptosis facilitator BIMEL when and during the 
growth of primary tumors in vivo. MDA-MB-231 
variants were orthotopically transplanted into the 
mammary fatpad of SCID mice. Mice were sacrificed 






















































Results Figure 16. Restoration BIN3 expression 
restore P38-signaling in vitro and in vivo. Western blots 
showing that restoration of BIN3 expression enhances the 
activation of P38-α and expression of BIMEL (a) during 
anoikis in vitro and (b) during the growth of primary 
tumors in vivo. HCC-38 variants were plated in 
suspension for 72 hours and BIN3 and P38 
phosphorylation levels were assessed by Western Blot. 
HCC-38 variants were orthotopically transplanted and 
after 4 weeks mice wre sacrificed and protein was 
extracted from tumors. (c) Western blots showing the 
activation (phosphorylation) of P38-α, the induction of 
the apoptosis facilitator BimEL and the levels of BIN3, 
P38, phosphorylated P38, CDC42, and TUBA in control 
and BIN3 knocked-down cells when these cells are 
exposed to anoikis in vitro. Cells were plated in 







Results Figure 17. BIN3 regulates anoikis via CDC42 and P38α. (a) Cell fractionation 
showing the reclocation of BIN3, CDC42, TUBA from the cytoplasm to the membrane during 
anoikis. MCF-10A-TM variants were plated in suspension for 24 hours and localization of 
proteins were assessed by Western Blot. TUBULIN is a control to show proper separation of 
the Cytosol, EGFR is a control to show proper separation of the membrane, HISTONE3 shows 
proper separation of the nucleus. (b) Immunofluorescence (IF) studies showing the independent 
cytoplasmic localization of BIN3, CDC42, and TUBA when cells are attached and show that a 
significant fraction of these proteins colocalize at the cell membrane when cells are exposed to 
anoikis. MCF-10A-TM variants were plated in suspension for 24 hours and localization of 
proteins was assessed by IF.In the IF panel additional 3D projection and intensity profile 
information of the channels is provided for cells in anoikis. The white arrow in the 3D image 
indicates the direction of the intensity profile. Green fluorescence= BIN3; Red Fluorescence=  













Results Figure 18. Loss of BIN3 leads to mislocalization of TUBA during anoikis and 
compromises CDC42 activation. (a) Immunoprecipitation (IP) studies showing that TUBA 
and BIN3 co-IP during anoikis. MCF-10A-TM cells were plated in suspension for 24 hours and 
IP of V5-tag was done and western blot against TUBA. (b) Cell fractionation experiments and 
(c) IF showing reduced relocation of TUBA at the cell membrane after detachment in BIN3-
knock-down cells (d) CDC42 activation assay showing that CDC42 is activated (bound to GTP) 














! Results Figure 19. CDC42 activation is downstream of BIN3 during anoikis. (a) 
Experimental activation of CDC42 by addition of a Rho activator to the culture media restores 
the sensitivity of BIN3 knockdown cells to anoikis conditions (left panel) and restores the 
phosphorylation levels of P38α. (b) Inhibition of CDC42 by adding the specific inhibitor 
ML141 increases the survival of cells in anoikis conditions and inhibits the phosphorylation of 









Results Figure 20. Proposed mechanistic model. When cells are attached BIN3, CDC42, 
TUBA exist independently in the cytosol. When cells are detached BIN3 and TUBA complex 
and BIN3 localizes TUBA to the membrane. TUBA then activates CDC42, which, in turn. leads 
to the activation of P38, anoikis signaling, and death. In the absence of BIN3, TUBA is not 
localized to the membrane, which disrupts the activation of CDC42 and , in turn,  the  disruption 

























Allelic loss of the short arm of human chromosome of 8 (8p) is one of the most common 
events in tumorigenesis, especially in breast cancer tumorigenesis.  To date, there has yet to be 
fully successful identification of the tumor suppressor in this region. In contrast to previous 
studies that choose genes in this hot spot region to validate as potential tumor suppressors, we 
utilized both genetic (anoikis screens) and genomic techniques (ISAR_DEL) to identify in an 
unbiased way BIN3 as a putative tumor suppressor located in this highly deleted region. The 
BIN3 locus is located at 8p21.3 within the most highly deleted portion of 8p (Cher et al., 1996) 
and within the portion that most likely contains the important tumor suppressor. 
Here, we showed that loss of BIN3 locus occurs about 50% of breast cancers (Fig. 5a) 
and loss of the locus correlated with poor prognosis characteristics, such as higher tumor grade 
(Fig. 6a), lymph node infiltration (Fig. 6b), and decreased survival (Fig. 7b) in breast cancer 
patients. Furthermore, loss of BIN3 conferred increased anoikis resistance in vitro and in vivo 
(Fig. 8b, 8c, 9b). Deletion of 8p is especially enriched in metastatic cancers (Cher et al., 1996; 
Macoska et al., 1994) and metastatic breast cancers (Anbazhagan et al., 1998; Venter et al., 
2005; Yokota et al., 1999), which suggests that the potential tumor suppressor housed at 8p plays 
a role in metastasis. Our data confirmed, through in vivo assays, that loss of BIN3 increased 
metastatic potential of breast cancer cells (Fig. 10a) in accordance with the suspected tumor 
suppressor in this region.  
In accordance with the function of a tumor suppressor, the re-expression of BIN3 was 
able to reduce tumorignecity and rescue the loss of function phenotype; re-expression of BIN3 
into cell lines that have homozygous deletion of the BIN3 locus reduced anoikis resistance in 




BIN3 is ubiquitously expressed, except in the brain (Routhier et al., 2001). Results from 
Xue et al. (Xue et al., 2012) and Scuoppo et al.!(Scuoppo et al., 2012) implicate BIN3 in tumor 
suppression in liver cancer and lymphomas, respectively, while results from Ramalingam et al. 
(Ramalingam et al., 2008) implicate BIN3 in tumor suppression in lymphomas and lung cancer 
and our results implicate BIN3 in tumor suppression in breast cancer. All these data support 
BIN3 as a putative tumor suppressor in the 8p21 region that is widely expressed in various 
tissues and that plays a role in tumor suppression in the various types of cancers, thus making 
BIN3 an ideal candidate for the widely deleted tumor suppressor on 8p.  
Previous to our study, the function of BIN3 in mammalian cells had not been fully 
elucidated. Ramalingam et al. (Ramalingam et al., 2008) concluded that BIN3 plays an unknown 
role in tumor suppression. During their studies, they found that MEFs derived from Bin3 
knockout mice showed increased viability in suspension, similar to the results of our study. Our 
study shows conclusively that BIN3 plays a role in tumor suppression by being a sensor, 
regulator, and inducer of anoikis, which results in the abrogation of metastasis and primary 
tumor growth.   
Resistance to anoikis is not only advantageous for metastasis (Zhu et al., 2001), but also 
primary tumor growth; sensitizing cancer cells to anoikis reduces primary tumor growth (Frankel 
et al., 2001). Antiapoptopic BCL-2 family member, BCL-XL is a protector against anoikis 
(Rosen et al., 2001). Protection from anoikis mediated by BCL-XL occurs either through its 
ability to bind and sequester BH3-only apoptosis activators (BIMEL) or its ability to associate 
with BAX to prevent from BAX oligomerizing and releasing CYTOCHROME C (Cheng et al., 
2001). When nonmalignant epithelial cells are detached from the ECM, BCL-XL is 




XL is able to circumvent anoikis even when cells are detached (Johnson and Boise, 1999). In 
cancerous cells, BCL-XL is not downregulated when cells are detached, thus, promoting anoikis 
resistance. When BCL-XL was knocked down in a highly tumorigenic ovarian cell line, the 
previously anoikis-resistant cell line was sensitive to detachment and cell death (Frankel et al., 
2001). Moreover, when these cells were transplanted into nude mice, the tumors were 
significantly smaller than control’s tumors (Frankel et al., 2001). Thus, rendering cancerous cells 
susceptible to anoikis and decreases primary tumor growth and tumorignecity; directly linking 
anoikis resistance to primary tumor growth. Therefore, since BIN3 is a regulator of anoikis, 
BIN3 is also a regulator of primary tumor growth. Loss of BIN3 increases tumor growth (Fig. 
10b), while re-expression of BIN3 in tumorigenic cells reduces tumor growth (Fig. 14a). 
Escape from anoikis aids primary tumor growth by allowing cancerous cells to be able to 
grow in the absence of correct proliferation signals. Normally, cells require signals, such as 
growth factors, attachment to ECM components, and cell-to-cell adhesion, before they move into 
an active proliferative state; without these signals, cells cannot proliferate. These signals are 
transmitted to the cells by transmembrane receptors and integrins. Tumor cells are liberated from 
this dependence on stimulation and signals from their normal tissue microenvironment (Hanahan 
and Weinberg, 2000) and are able to sustain chronic proliferation  in the absence of these signals, 
one of the hallmarks of cancer (Hanahan and Weinberg, 2011). Chronic proliferation also 
eventually results in the relocation of cells from their correct microenvironment to inappropriate 
environments, disrupting proper integrin to cell matrix interactions. Disruption of cell to matrix 
interactions and integrin binding normally causes cell cycle arrest and anoikis (Frisch and 
Ruoslahti, 1997). Therefore, anoikis ensures that cells in inappropriate locations are eliminated 




to escape the requirement of integrin ECM interactions, and to exhibit anchorage-independent 
growth (growth in absence of solid substratum) (Guadamillas et al., 2011). The ability to exhibit 
anchorage-independent cell growth and form colonies in semisolid media has been utilized as a 
marker for in vitro transformation and has been associated with tumorigenic and metastatic 
potential in vivo (Freedman and Shin, 1974). BIN3 loss promotes and increases anchorage-
independent growth (Fig. 9a), while the re-expression of BIN3 decreases colony formation (Fig 
13a.), thus, through modulation of anoikis BIN3 regulates anchorage –independent growth and 
primary tumor growth. 
The ability of BIN3 to regulate anoikis and tumor growth is exerted through the role 
BIN3 plays in the activation of CDC42. During anoikis, BIN3 is upregulated (Fig. 15b), it 
complexes with TUBA (Fig. 18a), and both move from the cytosol to the membrane (Fig. 17a 
and 17b). CDC42 also moves from the cytosol to the membrane (Fig. 17a and 17b) and the 
activity of CDC42 increases during anoikis (Fig. 18d). Knock down of BIN3 resulted in the 
mislocalization of TUBA during anoikis (Fig. 18b and c). This mislocalization of TUBA resulted 
in significantly less activation of CDC42 during anoikis (Fig. 18d) and the disruption of anoikis-
signaling. All together, these data suggest that BIN3 is required for the correct spatial temporal 
localization of TUBA to the membrane to ensure that TUBA is correctly positioned to activate 
CDC42 and trigger anoikis-signaling. Therefore, the role of BIN3 in the regulation of anoikis 
and tumor growth is through TUBA and CDC42. 
The DBL homology (DH) domain of TUBA activates only CDC42 (and not RAC1 nor 
RHO) (Salazar et al., 2003). TUBA is a unique GEF in that instead of having a pleckstrin 
homology (PH) domain downstream of the DH domain like almost all other GEFs, TUBA has 




responsible for the exchange from GDP to GTP for GTPases, while the PH domain targets and 
recruits GEFs to lipid membranes (Chhatriwala et al., 2007). The BAR domain of TUBA is 
postulated to functionally replace the PH domain and favor the action of TUBA highly curved 
membranes. TUBA is able to bind liposomes (artificially-prepared vesicles composed of a 
circular, curved lipid bilayer used to assay curved membrane binding), suggesting that TUBA is 
able to bind curved membranes. The BAR domain of TUBA is essential for binding liposomes 
(Cestra et al., 2005) and for correct localization of TUBA (Kovacs et al., 2006). Although TUBA 
is able to bind curved membranes (possibly through interaction between of the positive concave 
face of the BAR domain and the negative phospholipids of the membrane (Peter et al., 2004)), 
TUBA lacks an N-terminal α-helix (Suetsugu, 2010). Lacking a N-terminal α-helix may prevent 
TUBA from sensing and discerning the curved membrane in detached cells. Thus, the N-terminal 
α-helix of BIN3 is needed to sense the membrane curvature and ensure proper TUBA 
localization. Furthermore, the BAR domain is well known to mediate dimerization, both 
homodimerization and heterodimerization (Capraro et al., 2013; Peter et al., 2004). It is possible 
that TUBA interacts with BIN3 through their BAR domains, and this allows BIN3 to localize 
TUBA to the membrane to activate CDC42 during anoikis. BIN3 and TUBA have previously 
been shown to interact in prostate cells (Thalappilly et al., 2008); this interaction was confirmed 
during our studies (Fig. 18a).  
The S. pombe homolog of TUBA, gef1, was previously shown to interact and complex 
with the S.pombe homolog of BIN3, hob3p and the CDC42 homolog, cdc42p (Coll et al., 2007). 
During cytokinesis, hob3p localizes cdc42p to the division site and brings together cdc42p and 
gef1p to allow cdc42p to be activated by gef1. By ensuring the activation of cdc42p, hob3p 




disrupted. Human BIN3 was able to complement hob3p deletion and restore cdc42p localization 
and activation, suggesting that the role of BIN3 in CDC42 activation may be conserved in higher 
eukaryotes (Coll et al., 2007), which was confirmed by Simionescu-Bankston et al. (Simionescu-
Bankston et al., 2013) in myoctyes and muscle cells and further cemented by our work here.  
Unlike BIN3, hob3p is not required for the correct localization of gef1, but hob3p is 
necessary for the activation of cdc42p by gef1; loss of hob3p and loss of gef1 had similarly low 
levels of active cdc42p (Coll et al., 2007), suggesting that loss of hob3p is functionally similar as 
not having gef1 and that hob3p is essential for the ability of gef1 to activate cdc42p. Thus, hob3p 
not only plays a rold in correctly localizing cdc42p, but hob3p is needed to properly orient gef1 
and cdc42p to allow gef1 to activate cdc42p. Taking cues from their yeast homologs, it is 
possible to postulate that even if TUBA was able to localize to membranes in the absence of 
BIN3 (possibly through protein modifications, such as myristoylation or palmitoylation, which 
target proteins to the membranes (Resh, 1999) or even target proteins to curved membranes 
(Gerlach et al., 2010)), that correctly localized TUBA would still not be able to activate CDC42 
in the absence BIN3. Thus, stressing the importance BIN3 in CDC42 activation and anoikis. 
Though the role of BIN3 in the activation of CDC42 is conserved from yeast to humans, 
there are differences in how BIN3 plays a role in the activation of CDC42 in higher eukaryotes. 
In contrast to hob3p, BIN3 is not required for the proper localization of CDC42 during 
cytokinesis and cell division. Data from MEFs derived from Bin3 knockout mice did not show 
any differences in CDC42 expression or localization (Ramalingam et al., 2008). Furthermore, 
knockout of Cdc42 is early embryonic lethal (Chen et al., 2000), while Bin3 knockout mice were 
viable and fertile. Ramalingam et al. used these observations to suggest that there was a 




conclusion may have been premature. Our results concur with Ramalingam et al. in that, in 
higher eukaryotes, BIN3 is not responsible for the localization of CDC42 during cell division (as 
evidenced by the fact that loss of BIN3 does not affect proliferation rates (Fig. 10c)) or during 
anoikis, but what seems to be conserved is the role of BIN3 as a sensor of curved membrane 
(either membranes of dividing cells in yeast or rounded membranes from detached cells) and 
translating that information to lead the activation of CDC42, the role of BIN3 in ensuring the 
interaction between CDC42 and its GEF, and BIN3 in promoting the activation of CDC42 by its 
GEF. Ramalingam et al. do not report assessing the activation of CDC42 in their system, thus, 
they cannot accurately assess if there has been a divergence of function from yeast in higher 
eukaryotes; results from Simionescu-Bankston et al. (Simionescu-Bankston et al., 2013) and our 
work here suggest differently from their conclusions. Another difference between the role of 
BIN3 and hob3p is that BIN3 is required for the correct localization of the TUBA rather than 
CDC42, while hob3p loss did not affect the localization of gef1 (Coll et al., 2007). Despite these 
differences, the role of BIN3 is conserved to sense curved membranes and ensure activation of 
CDC42 by bringing together CDC42 with its activator TUBA.  
In primary tumors, loss of the BIN3 locus is significantly associated with less 
phosphorylation and activation of P38α (Fig. 15a). During detachment, when BIN3 is abrogated, 
CDC42 activity is attenuated, and P38α activation is disrupted (Fig. 15b). CDC42 has previously 
been shown to lead to the activation of P38α in many different tissues and in response to many 
different stresses (Bagrodia et al., 1995; Zhang et al., 1995), including disruption of matrix 
attachment (Bourdoulous et al., 1998). Experimental restoration of CDC42 activation, by a small 
protein modulator that is able to lock CDC42 in the active state and circumvent the requirement 




and anoikis (Fig. 19a). Contrarily, inhibition of CDC42 activity, by ML141, in wild type cells 
mimicked the loss of BIN3, dampened the activation of P38α, and rescued cells from anoikis 
(Fig. 19b), suggesting that BIN3 acts via CDC42 to regulate P38α and lead to BIMEL 
upregulation and cell death.  Here, we confirmed the regulation of P38α by CDC42 in mammary 
epithelial cells.  Futhermore, we have elucidated the upstream components of the anoikis, P38-
singlaing pathway, BIN3, TUBA, and CDC42. Further work needs to be done to discern the 
immediate(s) between CDC42 and P38α.  
While the role antitumorigenic role of P38 in primary tumor growth is well established 
(Brancho et al., 2003; Bulavin et al., 2004; Porras et al., 2004), the role of P38 in metastasis is 
more complex; there are stages in which P38 exerts a pro-metastatic role (invasion, migration, 
extravasation), while P38 plays an anti-metastatic role during the detachment of cell form the 
primary site and anoikis resistance (del Barco Barrantes and Nebreda, 2012). In support of the 
anti-metastatic role of P38, expression of P38 activators MKK4 and MKK6 both suppress 
metastasis through P38 pathway (Hickson et al., 2006). In metastatic cells, high P38 to ERK 
ratio favors growth arrest and dormancy, while low P38 to ERK ratio favors proliferation and 
metastatic growth (Aguirre-Ghiso et al., 2004). Our results contributes to the literature that 
suggests supplants the role of P38 in anoikis signaling contributes to protection against 
metastasis in breast cancer. 
Contrarily, CDC42 has been previously implicated in anoikis as having a protective role 
against anoikis (Cheng et al., 2004; Zugasti et al., 2001), which is in direct contrast to our results. 
The contribution of CDC42 to cancer progression appears to be both tissue-specific and context-
specific. There is evidence that CDC42 has pro-tumorigenic effects (Kamai et al., 2004; Mahajan 




(Stengel and Zheng, 2011; van Hengel et al., 2008; Zuo et al., 2012). This dual role in 
carcinogenesis of CDC42 (Stengel and Zheng, 2011) is probably a result of the wide array of 
CDC42 targets. 
 Speaking toward the protective role of CDC42 in tumorigenesis, loss of CDC42 in 
conditional knockout in the liver resulted in development of hepotacellular carcinoma (van 
Hengel et al., 2008). Similar to BIN3, RNAi against CDC42 reduced metastasis in breast cancer 
cells (Zuo et al., 2012). Furthermore, CDC42 is housed at 1p36, a region that is commonly 
deleted (Farabegoli et al., 1996; Hainsworth et al., 1992) in 30-60% of breast cancers 
(Ragnarsson et al., 1996), including invasive breast cancers (Bieche et al., 1999), which may 
suggest CDC42 has a protective role in breast cancers and metastatic breast cancers. 
Accordingly, our results suggest a protective role for CDC42 in anoikis and metastatic breast 
cancers. 
Finally, our results suggest a model in which changes in cell shape, cell rounding, and 
higher curvature caused by detachment, is sensed by the N-terminal α-helix of N-BAR protein 
BIN3; the detached signal is translated via CDC42 to lead to P38α-signaling and anoikis. BIN3 
utilizes its N-terminal α-helix to insert into the packing defects of highly curved membrane. 
Also, possibly using its BAR domain, BIN3 complexes with TUBA and localizes TUBA to the 
curved membrane. Once located at the membrane, TUBA activates CDC42; activation of CDC42 
leads to the activation of P38α and cell death. Our work links shape-dependent-regulation of 
anoikis to P38-signaling, thus, linking two previously unlinked known regulators of anoikis.  
Next experiments, will aim to elucidate the regulation of BIN3. Our data suggests that 
BIN3 protein levels are hardly detectable when cells are attached (Fig. 15a), but when cells are 




that suggests that BIN3 protein levels are strongly upregulated as soon as one hour after 
detachment (data not shown). Interestingly, BIN3 mRNA levels do start to increase until about 
12 hours after detachment, suggesting that the sharp upregulation in BIN3 protein levels are not a 
result of transcriptional upregulation. It is possible that this increase in protein level is a result of 
protein stabilization. Future experiments will be aimed at understanding how BIN3 is regulation 
and stabilized by detachment to exert its antitumorigenic function. 
To date, there have been 16 mutations identified in BIN3 amongst patient samples 
(http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/), five of which are missense, two are 
nonsense, and two are frameshift mutations. Future experiments will aim to test the functional 
effects of these mutations on BIN3 and identify residues or regions that are essential for BIN3 
functions: sensing and binding membranes, interacting with TUBA, aiding the activation of 
CDC42, anoikis, protein stabilization, in an effort to better understand the protein structure of 
BIN3 and better understand how BIN3 functions, in hopes of one day harnessing and exploiting 
the antimorigenic functions of BIN3. 
 Here, we have confirmed BIN3 as a novel tumor suppressor, elucidated novel regulators 
of anoikis, gained deeper understanding of the molecular cues that regulate anoikis, and aided the 
search for novel therapeutic targets. Our work suggests that not only anoikis important for the 
prevention of metastasis, but also primary tumor growth. BIN3 appears to exert its pro-apoptopic 
function exclusively in rounded, detached cells; re-expression or over-expression did not affect 
the viability or proliferation rate (Fig.14b; data not shown) of cells in culture, suggesting that 
BIN3 may be selectively utilized against detached cells. Hatzaki et al., (Hatzakis et al., 2009) 
found that when membrane curvature is not high, there are infrequent, small lipid packing defect 




absorption is disfavored. These data suggest that BIN3 would only be able to bind membranes, 
engage TUBA and CDC42, have pro-apoptopic effects in rounded, detached cells. Further work 
needs to be done on how to exploit BIN3 detachment sensing properties for novel therapies 
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